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Nicotine Self-administration and after Extinction in Rats
Abstract
The mesocorticolimbic pathway is critical in almost all aspects of drug abuse, including nicotine. Though
many of the neurochemical and molecular effects of nicotine have been well studied, nicotine’s long-term
neuroadaptive effects, specifically within the mesocorticolimbic pathway, are largely undefined. Thus, in
current study, we determined the neuroadaptive changes in the mesocortical glutamatergic system during
chronic nicotine self-administration (SA), which emulates important aspects of nicotine intake by
humans, and after extinction. In the initial study, after 18 days of nicotine SA, in the medial prefrontal
cortex (mPFC), NMDA receptor subunit 2A (NR2A) and NR2B were increased by 67% and 83%,
respectively. In the ventral tegmental area (VTA), glutamate receptor subunit 2/3 (GluR2/3) was increased
by 34%. These findings suggest the glutamate neurotransmission between mPFC and VTA may be
enhanced during chronic nicotine SA. Thus, we determined the effects of nicotine SA and extinction on
NMDA-induced glutamate neurotransmission between mPFC and VTA. On d 19 of ad lib access to
nicotine SA, both brain regions were microdialyzed for glutamate while mPFC was sequentially perfused
with: Kreb’s Ringer Buffer (KRB), 200 mM NMDA, KRB, 500 mM NMDA, KRB, 100 mM KCl. Basal glutamate
levels were unaffected, but nicotine SA potentiated mPFC glutamate release to 200 mM NMDA, which
was ineffective in controls. Furthermore, in VTA, nicotine SA amplified glutamate responses to both mPFC
infusions of NMDA. After extinction, glutamate responses were no longer enhanced, and the expression
of glutamate receptor subunits reverted to control levels. Behavioral studies showed that an mPFC
microinjection of AP-5, an NMDA-R antagonist, did not affect nicotine or sucrose SA on d 19. In contrast,
in VTA, NBQX, an AMPA-R antagonist, attenuated both nicotine and sucrose SA. In summary, chronic
nicotine SA amplified both mPFC and VTA glutamate responses to mPFC NMDA. This hyperresponsiveness, along with the up-regulation of glutamate receptors, reverted to control levels after
extinction. Blockade of VTA AMPA-R but not mPFC NMDA-R, decreased nicotine and sucrose SA.
Collectively, these studies indicate that mesocortical glutamate neurotransmission adapts to chronic
nicotine SA and up-regulation of VTA AMPA-R may be involved in the maintenance of nicotine SA.
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Abstract
The mesocorticolimbic pathway is critical in almost all aspects of drug abuse,
including nicotine. Though many of the neurochemical and molecular effects of nicotine
have been well studied, nicotine’s long-term neuroadaptive effects, specifically within the
mesocorticolimbic pathway, are largely undefined. Thus, in current study, we determined
the neuroadaptive changes in the mesocortical glutamatergic system during chronic
nicotine self-administration (SA), which emulates important aspects of nicotine intake by
humans, and after extinction. In the initial study, after 18 days of nicotine SA, in the
medial prefrontal cortex (mPFC), NMDA receptor subunit 2A (NR2A) and NR2B were
increased by 67% and 83%, respectively. In the ventral tegmental area (VTA), glutamate
receptor subunit 2/3 (GluR2/3) was increased by 34%. These findings suggest the
glutamate neurotransmission between mPFC and VTA may be enhanced during chronic
nicotine SA. Thus, we determined the effects of nicotine SA and extinction on NMDAinduced glutamate neurotransmission between mPFC and VTA. On d 19 of ad lib access
to nicotine SA, both brain regions were microdialyzed for glutamate while mPFC was
sequentially perfused with: Kreb’s Ringer Buffer (KRB), 200 µM NMDA, KRB, 500 µM
NMDA, KRB, 100 mM KCl. Basal glutamate levels were unaffected, but nicotine SA
potentiated mPFC glutamate release to 200 µM NMDA, which was ineffective in
controls. Furthermore, in VTA, nicotine SA amplified glutamate responses to both mPFC
infusions of NMDA. After extinction, glutamate responses were no longer enhanced, and
the expression of glutamate receptor subunits reverted to control levels. Behavioral
studies showed that an mPFC microinjection of AP-5, an NMDA-R antagonist, did not
affect nicotine or sucrose SA on d 19. In contrast, in VTA, NBQX, an AMPA-R
antagonist, attenuated both nicotine and sucrose SA. In summary, chronic nicotine SA
amplified both mPFC and VTA glutamate responses to mPFC NMDA. This hyperresponsiveness, along with the up-regulation of glutamate receptors, reverted to control
levels after extinction. Blockade of VTA AMPA-R but not mPFC NMDA-R, decreased
nicotine and sucrose SA. Collectively, these studies indicate that mesocortical glutamate
neurotransmission adapts to chronic nicotine SA and up-regulation of VTA AMPA-R
may be involved in the maintenance of nicotine SA.
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Chapter 1. Introduction
1.1. Epidemiology of nicotine abuse and addiction
Nicotine, an addictive substance, is the major psychoactive component in
cigarette smoke. Despite the recent trend that suggests a declining prevalence of active
tobacco users (Giovino et al., 1995; Hudmon et al., 2006), tobacco use in the form of
cigarette smoking is still responsible for three million smoking related deaths in the
United States and approximately 20% of all deaths in the western world (Smith and
Fiore, 1999). According to the Centers for Disease Control and Prevention (CDC), nearly
438,000 deaths and $157 billion in annual health-related economic losses are attributable
to cigarette smoking in the United States (CDC, 2002; 2005). Worldwide, smokingrelated mortality is predicted to exceed 10 million individuals per year in the coming 3040 years (Peto et al., 1996). All of these statistics yield one conclusion: nicotine abuse in
the form of cigarette smoking is a global health epidemic. It is the leading preventable
cause of morbidity and death in the United States (Koop and Luoto, 1982; Smith and
Fiore, 1999).

1.2. Neuropharmacology of nicotine addiction
1.2.1. General mechanisms of nicotine addiction: from molecular to cellular level
Nicotine exerts its central and peripheral actions by binding to nicotinic
acetylcholine receptors (nAChRs) that are cationic ligand-gated ion channels expressed
throughout the central nervous system (CNS). Currently, twelve neuronal nAChRs
subunits have been identified and cloned: α2-α10 and β2-β4 (Dani and Bertrand, 2007) .
In contrast to the highly conserved primary structure of muscle type nAChRs (Le Novere
and Changeux, 1995), the primary structures of neuronal nAChRs are highly diverse. In
general, neuronal nAChRs can be divided into two categories: heteromeric and
homomeric. α7-α9 subunits are capable of forming homooligomeric nAChRs, but only
α7 is present throughout the mammalian CNS (Dani et al., 2001). The functional
properties of nAChRs vary depending on the composition of the subunits. For example,
the relative permeability of calcium compared to sodium ranges from 0.1 for muscle type
nAChRs to 2.0 for neuronal type heteromeric nAChRs and to greater than 10 for neuronal
homomeric nAChRs (Dani and Bertrand, 2007). In addition, the potency of acetylcholine
in an electrophysiological study varies as well; it has been shown that α7 subunit requires
a higher concentration of acetylcholine for activation (EC50: approximately 200 µM) in
comparison to α4β2 (EC50: 62 µM and 1.6 µM for low and high affinity component,
respectively) (Buisson and Bertrand, 2001).
Distinct pharmacological profiles, dependent on subunit composition, have given
rise to selective ligands. Highly selective α7 homomeric receptor antagonists such as α1

bungarotoxin (αBgtx) (Katz and Miledi, 1973) and methyllycaconitine (MLA; at nM
concentrations), which has very high affinity for the rat brain αBgtx binding site (Ward et
al., 1990), have been discovered. Epibatidine, which binds with pM affinity to all of the
receptors containing α2, α3, α4, α6 and α8 subunits, is used frequently in receptor
binding studies as an agonist for heteromeric nAChRs (Gotti et al., 2000). The
noncompetitive nAChR antagonist mecamylamine has been used widely; however, it also
showed non-specific inhibition of the NMDA receptor at high micromolar
concentrations. Dihydro-beta-erythroidine (DHβE) and alpha-conotoxin-MII (α-CTxMII) have been identified as selective antagonists for α4β2 and α3β2/α6β2 nAChRs,
respectively (Alkondon and Albuquerque, 1993; Cartier et al., 1996).
In the brain, upon binding of nicotine or endogenous acetylcholine, nAChR
channels open and cations flux inward, resulting in neuronal depolarization. Depending
on the location of the nAChRs, activation of nAChRs has different effects on neurons.
The activation of nAChRs on post-synaptic neurons triggers some of the fast excitatory
neurotransmission and many cellular processes including the modulation of cytoplasmic
signal transduction affecting extracellular signal-regulated kinase (ERK) and cyclic
adenosine 3’,5’-phosphate (cAMP)-responsive element binding protein (CREB) (Dani
and De Biasi, 2001). By using whole cell recording and optical recording techniques, fast
postsynaptic currents mediated by acetylcholine were discovered first in the developing
visual cortex of ferrets (Roerig et al., 1997). Under the condition of blockade of
muscarinic, AMPA, NMDA, γ-aminobutyric acid receptor subtype A (GABAA), ATP,
and 5-HT3 receptors, α7 subunit-containing nAChRs are thought to be the major
nAChRs mediating the fast excitatory neurotransmission recorded in CA1 interneurons
from hippocampal slice preparations (Alkondon et al., 1998; Frazier et al., 1998). The
activation of α7 nAChRs results in a short-lasting phasic excitation of CA1 interneurons,
while α4β2 nAChRs are thought to mediate the long-lasting tonic excitation of these
interneurons (Alkondon, Pereira et al., 1999). Interestingly, α4β2 containinig nAchR has
been shown to be involved in fast synaptic neurotransmission in the chick lateral
spiriform nucleus (SpL) (Nong et al., 1999). Therefore, the excitability of neurons can be
modulated by nicotinic cholinergic inputs.
The activation of presynaptic α7 subunit-containing nAChRs or preterminal
nAChRs stimulates the release of a number of neurotransmitters by calcium influx. These
include dopamine, glutamate and GABA (Dani and De Biasi, 2001). It has been reported
that intravenous nicotine increases extracellular dopamine levels in the nucleus
accumbens (NAcc) shell, which is thought to be a neurochemical effect common to drugs
of abuse (Pontieri et al., 1996). Glutamate release was enhanced when presynaptic
nAChRs on glutamatergic terminals between medial habenula nucleus (MHN) and the
interpeduncular nucleus (IPN) were activated by the acute administration of nicotine
(McGehee et al., 1995). Similarly, nicotine enhanced GABA release in cultured
hippocampus neurons. The functional significance of interactions between nicotine and
specific neurotransmitter systems is elaborated in the following section.
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1.2.2. Neuroanatomy of the mesocorticolimbic system and neurotransmitter and
receptor systems important for nicotine abuse
1.2.2.1. Neuroanatomy of the mesocorticolimbic system
The mesocorticolimbic system is composed of the mPFC, VTA and NAcc, as well
as other limbic regions including the striatum and amygdala. Pyramidal neurons in the
mPFC send excitatory glutamatergic projections to the VTA and the NAcc as well as
other subcortical regions (Sesack and Pickel, 1992; Taber et al., 1995). The mPFC
receives dopaminergic innervations from the VTA (Thierry et al., 1973; Sesack et al.,
1995). The mPFC also receives cortical glutamatergic inputs from the contralateral mPFC
(Conde et al., 1995) and subcortical glutamatergic inputs from the medialdorsal thalamus
(MD) (Thierry et al., 1973; Pirot et al., 1994), the CA1 region of hippocampus (Jay et al.,
1989; Jay et al., 1996; Thierry et al., 2000) and the basolateral nucleus of the amygdala
(BLA) (Bacon et al., 1996; McDonald, 1996). GABAergic inputs to the mPFC pyramidal
neurons originate from mPFC GABAergic interneurons and GABA-containing neurons
in the VTA (Pirot et al., 1992; Carr and Sesack, 2000).
The mPFC is a heterogenerous region and can be further divided into five
subregions: infralimbic, dorsal and ventral anterior cingulate (areas Cg1 and Cg2,
respectively), prelimbic (area Cg3) and medial precentral (Fr1) (Steketee, 2005). It has
been shown that prelimbic and infralimbic cortices receive strong dopaminergic inputs
from the A10 cell group of the VTA (Thierry et al., 1973; Lindvall and Bjorklund, 1978;
Sesack et al., 1995). Quinolinic acid lesions of the prelimbic subregion selectively block
the initiation of cocaine-induced sensitization while the same lesions of the infralimbic
subregion disrupt spontaneous motor activity (Tzschentke and Schmidt, 2000). In
general, the ventral mPFC projects mainly to the shell of the NAcc whereas the dorsal
mPFC neurons impinge primarily on neurons in the core of the NAcc (Berendse et al.,
1992). Furthermore, a recent tract tracing study demonstrated that the bulk of the NAcc
glutamate input arises from the ventral mPFC (Gabbott et al., 2005), moreover, this same
study suggested that VTA receives relatively homogenous input from the ventral and
dorsal mPFC (Gabbott et al., 2005). These neuroanatomical differences extend to the
functional differences between these two mPFC subregions. Functionally, lesions of the
dorsal mPFC (dorsal prelimbic and anterior cingulate) blocked the expression of
behavioral sensitization to cocaine (Pierce et al., 1998), while lesions of ventral mPFC
(ventral prelimbic and infralimbic) failed to do so (Tzschentke and Schmidt, 1999).
Traditionally, the VTA is thought to be composed of two types of neurons:
GABAergic and dopaminergic neurons (Johnson and North, 1992). VTA dopamine
neurons project to the NAcc and the mPFC. VTA GABAergic neurons project to the
mPFC (Carr and Sesack, 2000) and the NAcc (Van Bockstaele and Pickel, 1995), while
GABAergic interneurons synapse primarily on VTA DA neurons (Steketee, 2005).
Traditionally, the VTA is thought to receive excitatory inputs primarily from the mPFC
(Hurley et al., 1991), however, a recent paper provided new evidence that subcortical
3

regions (i.e., laterodorsal tegmental nucleus) are also important sources of glutamate to
the VTA (Omelchenko and Sesack, 2007). Moreover, mPFC glutamatergic projections to
the VTA seem to be target-specific: mPFC glutamatergic inputs selectively synapse on
mesoaccumbens GABAergic neurons in the VTA and on mesocortical dopaminergic
neurons (Carr and Sesack, 2000). Furthermore, a recent study showed that primary
glutamatergic neurons also exist in the VTA as evidenced by the presence of vesicular
glutamate transporter 2 (VGluT2) mRNA without co-expression of markers characteristic
of dopaminergic or GABAergic neurons (Yamaguchi et al., 2007). However, the
functional role of these intrinsic VTA glutamatergic neurons is unclear.
The mesolimbic dopaminergic pathway is thought to be a fundamental anatomical
substrate that mediates natural reward and the reinforcing effects of drugs of abuse (Wise,
1996; Wise, 2006). The NAcc receives dopaminergic and GABAergic inputs from the
VTA and receives glutamatergic inputs from the mPFC (Sesack and Pickel, 1992). The
NAcc also sends GABAergic projections back to the VTA. Thus, the NAcc is regulated
by the mPFC as well as the VTA. In the preceding sections, we have discussed the
different functional roles of the core vs. shell of the NAcc as well as the preferential
innervation from mPFC subregions (Groenewegen et al., 1990). Though this dissertation
focuses on the mPFC-VTA glutamatergic circuitry, this pathway must be understood in
the context of other neuroanatomical regions, regulatory circuits and neurotransmitters
within the mesocorticolimbic system (e.g. NAcc and inputs from other brain nuclei such
as serotonergics from dorsal raphe, and noadrenergics from locus coeruleus (LC), which
will be discussed extensively in the Discussion chapter).
1.2.2.2. Dopaminergic system
The dopamine hypothesis postulates that the mesolimbic dopaminergic system
has an important role in transducing the signals for reinforcement that are triggered by
natural rewards and drugs of abuses including nicotine (Spanagel and Weiss, 1999). It is
supported by the pivotal finding that drugs (e.g., nicotine, opiates, ethanol, amphetamine,
cocaine) increased extracellular dopamine levels in the NAcc of freely moving rats (Di
Chiara and Imperato, 1988). As mentioned above, nicotine is able to induce
neurotransmitter release by binding to and activating nAChRs. In situ hybridization
experiments have demonstrated that mRNAs for a majority of the neuronal nAChR
subunits (e.g., α2, α3, α4, α5, α6, α7, β2 and β3) are expressed in mesolimbic dopamine
regions (Di Chiara, 2000). Furthermore, β2, α6 and α4 subunits were found on dopamine
neurons in the VTA by immunohistochemistry (Di Chiara, 2000). These findings support
the idea that nicotine is capable of modulating dopamine neurotransmission.
Several lines of evidence have demonstrated that the dopaminergic system is
crucial for nicotine self-administration. The microinjection of 6- hydroxydopamine (6OHDA) into the NAcc, which selectively lesioned the mesolimbic dopamine system,
significantly reduced nicotine self-administration (SA) (Corrigall et al., 1992).
Furthermore, it has been demonstrated that systemic administration of both a selective D1
receptor antagonist (SCH23390) and a D2 receptor antagonist (spiperone) were able to
4

attenuate nicotine SA in a dose-dependent manner (Corrigall and Coen, 1991).
Collectively, these experiments indicate that the mesolimbic dopamine system has a
crucial role in mediating the reinforcing effects of nicotine.
Conditioned place preference is another animal model to study the reinforcing
effects of drugs of abuse. It is based on the observations that animals prefer the
environment that is paired with a positive motivational stimulus. The effects of nicotine
on conditioned place preference remain controversial. Both place aversion and preference
were reported when different doses of nicotine were directly infused into the VTA
(Laviolette and van der Kooy, 2003). Interestingly, both systemic and intra-accumbens
administration of the dopamine receptor antagonist, α- flupenthixol, were able to
potentiate nicotine place preference (Laviolette and van der Kooy, 2003). These
observations suggest that mesolimbic dopamine signaling might mediate some of the
aversive properties of nicotine, and thus blockade of mesolimbic dopamine signaling may
enhance the reinforcing effects of nicotine (Laviolette and van der Kooy, 2003).
D1 and D2 receptors have been shown to be involved in the reinforcing effects of
nicotine. For example, systemic administration of selective D1 (SCH23390) or D2
(spiperone) dopamine antagonists attenuated the maintenance of nicotine SA (Corrigall
and Coen, 1991). The D3 receptor localizes predominantly in limbic areas, and a
subpopulation appears to function as autoreceptors that modulate dopamine release
(Heidbreder et al., 2005). However, less is known regarding to the roles of D3 receptor
subtypes in nicotine addiction, largely due to the lack until recently of a selective D3
receptor antagonist. In 2003, the effects of a selective D3 receptor antagonist, SB277011-A (100 fold selectivity for D3 receptor subtype over D2), on the maintenance of
nicotine SA and on nicotine induced nicotine reinstatement were reported (Andreoli et
al., 2003). SB-277011-A (3-10 mg/kg, i.p.) substantially reduced nicotine priminginduced reinstatement, while it had no effect on the maintenance of nicotine SA
(Andreoli et al., 2003). This suggests that different dopamine receptor subtypes might
have distinct roles in nicotine abuse and addiction.
At the concentrations of nicotine found in the blood of smokers (Henningfield et
al., 1993), nicotine depolarizes the VTA dopamine neurons in a rat midbrain slice
preparation and then desensitizes within seconds (Pidoplichko et al., 1997). However,
enhanced dopamine release can last for more than one hour, as shown by in vivo
microdialysis (Imperato et al., 1986; Di Chiara and Imperato, 1988). This discrepancy
suggests that additional mechanisms may contribute to the sustained dopamine release
induced by transient nAChR activation.
1.2.2.3. Glutamatergic system
The glutamate system is the primary excitatory neurotransmitter system in the
CNS and has been shown to regulate the mesolimbic dopamine system -specifically the
A10 dopamine neurons in the VTA (Kalivas et al., 1989). Nicotine has also been shown
to enhance glutamate release in a number of brain regions across multiple species,
5

probably through presynaptic α7 subunit-containing nAChRs (Mansvelder and McGehee,
2000). Systemic nicotine (0.5 mg/kg, s.c.) significantly increased extracellular levels of
both aspartate and glutamate measured by in vivo microdialysis in the VTA (Schilstrom
et al., 2000). This enhanced glutamate release was blocked by intra-tegmental infusion of
the α7 nAChR antagonist methyllycaconitine (MLA; 0.3mM) (Schilstrom et al., 2000).
In an electrophysiology study, the α7 nAChR antagonist, α-BgTx, blocked the nAChRmediated spontaneous postsynaptic glutamate currents (PSC) in the chick ventral lateral
geniculate nucleus (Guo et al., 1998). Consistent with this study, it has been
demonstrated that local application of nicotine into the VTA enhanced glutamatergic
inputs (spontaneous EPSCs), which led to long-term potentiation (LTP) in a α7 receptordependent manner (McGehee et al., 1995; Mansvelder and McGehee, 2000). Similarly,
local application of nicotine enhanced glutamate release from the thalamocortical
terminals in a preparation of prefrontal cortex (Lambe et al., 2003).
A large number of reports have examined the functional significance of nicotineenhanced glutamate input to dopamine neurons. Several lines of evidences have
suggested that nicotine may modulate DA release by influencing presynaptic nAChRs on
glutamatergic inputs to dopamine neurons. In an in vivo microdialysis study (Schilstrom
et al., 1998), the enhanced dopamine release in the NAcc after systemic nicotine injection
was reduced by intra- tegmental perfusion of 2- amino- 5- phosphonopentanoic acid (AP5) but not by 6- cyano- 7- nitroquinoxaline- 2,3- dione (CNQX), suggesting a pivotal role
of VTA NMDA receptors in mediating the reinforcing effects of nicotine. Furthermore,
our laboratory has demonstrated that the increased dopamine release induced in the NAcc
by a low dose of nicotine (i.v. 0.065mg/kg) or a higher dose (0.09mg/kg) was abolished
or reduced by intra-tegmental administration of AP-5 (Fu et al., 2000). Moreover, the
level of VTA glutamate was only affected by higher doses of nicotine, indicating that the
enhancement of NAcc DA release by lower doses of nicotine involves the tonic
activation of VTA NMDA receptors (Fu et al., 2000). In line with these studies, systemic
administration of another NMDA receptor antagonist, MK-801 (dizocilpine), also
blocked nicotine-induced dopamine release in the NAcc (Sziraki, Sershen et al., 1998).
Surprisingly, systemic administration of the NR2B receptor antagonist, Ro 25-6981 (10
mg/kg i.p.), significantly potentiated nicotine-induced DA release in the NAcc, as well as
nicotine-induced locomotor activity (Kosowski and Liljequist, 2004). It is difficult to
reconcile this data that was obtained using a selective NMDA antagonist administered
systemically. Taken together, these reports suggest that NMDA receptors in the VTA are
pivotal in modulating nicotine-induced DA release in the NAcc, while studies using
receptor subtype selective antagonists or agonists might reveal the role of specific
NMDA receptor subtypes in nicotine-induced DA release.
There have been few studies to evaluate the role of the glutamate system in
animal models of nicotine reinforcement. One study demonstrated that an NMDA
receptor channel blocker, memantine, prevented acquisition of nicotine SA in mice
(Blokhina et al., 2005). However, memantine is not a selective NMDA receptor
antagonist, affecting other receptors as well, e.g., 5-HT3 receptor and nAChRs with
similar or lower potency (Blokhina et al., 2005). Thus, its potential inhibitory effects on
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the nicotinic receptor channel needs to be taken into consideration to interpret the data
accurately.
Metabotropic glutamate receptors (mGluR) are one of the G-protein coupled
receptors (GPCR) that have been shown to regulate neurotransmitter release by
modulating the activity of calcium and potassium channels (Cartmell and Schoepp,
2000). The mGluR5 receptor antagonist, MPEP, has been reported to reduce nicotine SA
in rats and in mice (Paterson et al., 2003) and to diminish nicotine-seeking behavior
induced by nicotine priming (Tessari et al., 2004), possibly by modulating mesolimbic
dopamine neurotransmission. In a follow-up experiment, increased glutamate
neurotransmission, induced by the inhibition of presynaptic inhibitory mGluR2/3
autoreceptors, was shown to diminish the effect of postsynaptic excitatory mGluR5
receptor blockade on nicotine SA (Liechti and Markou, 2007). Thus, metabotropic
glutamate receptors are implicated in nicotine reinforcement.
In summary, nicotine increases glutamate release by binding to presynaptic α7
receptors on glutamatergic terminals in mesocorticolimbic regions, including the VTA,
NAcc and PFC (Mansvelder and McGehee, 2000). Neuroanatomically, subcortical
glutamatergic inputs to VTA innervate the mesoaccumbens DA neurons (Omelchenko
and Sesack, 2007). Thus, NMDA receptors in the VTA, probably those expressed by
mesoaccumbens DA neurons, are pivotal in regulating DA release in the NAcc
(Schilstrom et al., 1998); however, only tonic activation of NMDA receptors in the VTA
was involved under low dose nicotine administration (Fu et al., 2000). The acquisition of
nicotine SA in mice was shown to be blocked by NMDA receptor channel blocker
memantine, though its nonspecific effects on other receptors limits the interpretation of
this data (Blokhina et al., 2005). Blockade of postsynaptic excitatory mGluR5 receptors
reduces nicotine SA in rats and mice (Paterson et al., 2003), which can be antagonized by
inhibiting presynaptic inhibitory mGluR2/3 receptors (Liechti and Markou, 2007).
Collectively, these observations implicate both ionotropic and metabotropic glutamate
receptors in mediating the reinforcing effects of nicotine, probably by regulating the
activity of VTA dopamine neurons.
1.2.2.4. Cholinergic and other systems
It has been proposed that brainstem cholinergic, GABAergic, noradrenergic and
serotonergic nuclei may be involved in mediating the reinforcing effects of nicotine
(Picciotto and Corrigall, 2002). The VTA dopamine neurons receive cholinergic inputs
from the caudal pedunculopontine tegmental nucleus (PPTg) and the adjacent
laterodorsal tegmental nucleus (LDTg) (Oakman et al., 1995). Electrical stimulation of
the laterodorsal tegmentum (LDT) evoked a three-component change in the NAcc DA
efflux, characterized by a initial increase with a mean peak current of +0.22 ± 0.05 nA
followed by a decrease in the DA signal with a mean maximal current of −0.23
± 0.05 nA, and a third prolonged enhancement of DA efflux with a mean peak current of
+0.88 ± 0.05 nA (Forster and Blaha, 2000). Both a intra-VTA microinjection of nAChR
antagonist, mecamylamine (5 µg/0.5µL), and ionotropic glutamate receptor (iGluR)
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antagonist, kynurenate (10µg/µL), attenuated the first facilitatory component by 77% and
59%, respectively, while sparing the second and the third components, indicating the
initial increase of DA efflux involves cholinergic and glutamatergic inputs to VTA DA
neurons from LDT and the nAChRs and iGluRs in the VTA (Forster and Blaha, 2000).
Intra-LDT infusion of either a nonselective muscarinic or a selective M2 receptor
antagonists, scopolamine (100 µg/µL) or methoctramine (50 µg/µL), respectively,
abolished the second component of NAcc dopamine release evoked by electrical
stimulation of LDT. These muscarinic antagonists inhibited the muscarinic M2
autoreceptors on LDT cholinergic neuron cell bodies, reducing the negative cholinergic
feedback (Forster and Blaha, 2000). The third component of DA efflux was reduced by
an intra-VTA microinjection of the muscarinic antagonist, scopolamine (200 µg/µL)
(Forster and Blaha, 2000). Collectively, these data support the notion that mesolimbic
dopaminergic neurons are regulated by both cholinergic and glutamatergic projections
from LDT to VTA. Both nAChRs and muscarinic cholinergic receptors in the VTA
mediate the effects of this cholinergic input.
Systemic nicotine (0.3 or 1.0 mg/kg, s.c.) has been shown to markedly increase cFos immunoreactivity in both PPTg and LDTg (Jose Lanca et al., 2000). To evaluate the
role of cholinergic neurons in PPTg in the maintenance of nicotine SA, ethylcholine
mustard aziridinium ion, a selective cholinergic toxin, was used to lesion the PPTg
cholinergic neurons (Lanca et al., 2000). Histological examination revealed an
approximate 70% reduction in NADPH-d positive neurons, which signify cholinergic
neurons in the PPTg (Lanca et al., 2000), while non-cholinergic neurons in the PPTg
were largely spared; this is indicative of a selective cholinergic lesion (Lanca et al.,
2000). This lesion was found to reduce nicotine SA by 40% after rats acquired stable
operant responding (Lanca et al., 2000). These experiments indicate that cholinergic
neurons in the PPTg as well as the LDTg play a role in nicotine SA by regulating VTA
dopamine neuronal activity.
It is known that VTA dopamine neurons receive GABAergic inputs not only from
local GABA interneurons but also from descending GABAergic inputs originating in the
ventral pallidum and NAcc (Walaas and Fonnum, 1979; Sugita et al., 1992). These
inhibitory inputs directly regulate the activity of VTA dopamine neurons, indirectly
affecting somatodendritic dopamine release and dopamine neuronal activity (Klitenick et
al., 1992). The inhibition of dopaminergic tone in the VTA by the GABAA receptor
agonist muscimol or GABAB receptor agonist baclofen has been shown to reduce the DA
release in the NAcc (Westerink et al., 1996). Gamma vinyl-GABA (GVG), which
increases GABA release, dose-dependently inhibited nicotine-induced dopamine release
in the NAcc; 100 and 150mg/kg GVG both abolished nicotine-induced dopamine release
(Dewey et al., 1999). A dose of 18.75mg/kg GVG completely blocked the expression of
nicotine induced CPP, and 75mg/kg dose abolished the acquisition of nicotine-induced
CPP (Dewey et al., 1999). Furthermore, GVG has been shown to reduce nicotine SA by
increasing GABA neurotransmission (Paterson and Markou, 2002). Somatodendritic
VTA dopamine regulates VTA DA neurons via tonic auto-inhibition, mediated by D2
auto-receptors located on the VTA DA neurons. D2 receptor agonists reduce the firing
rate of dopamine neurons and inhibit DA release in the VTA, while D2 receptor
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antagonists increase somatodendritic DA release in the VTA (Adell and Artigas, 2004).
Thus, the regulation of somatodendritic DA release is another mechanism whereby, the
GABA system is involved in regulating VTA dopamine neuronal activity.
The GABAB receptor has recently received greater attention than the GABAA
receptor due to the more selective expression of the VTA GABAB receptor and its effects
on the reinforcing properties of drugs of abuse. These two receptors are differentially
distributed in that GABAB receptors are largely expressed on the cell body of dopamine
neurons (Kalivas et al., 1993) while GABAA receptors are expressed on GABA
interneurons and the cell body of dopamine neurons (Klitenick et al., 1992). Indeed,
intra-tegmental infusion of the GABAB receptor agonists, baclofen, significantly reduced
nicotine SA (Corrigall et al., 2000). Acute systemic administration of the GABAB
agonists, baclofen (Fattore et al., 2002; Paterson et al., 2004) and CGP44532 (Paterson et
al., 2004; Paterson et al., 2005) also reduced nicotine SA and cue- induced nicotine
reinstatement, respectively. Moreover, repeated systemic administration of CGP44532
also decreased nicotine SA (Paterson et al., 2005). Taken together, these findings support
the hypothesis that GABAergic mechanisms may influence the reinforcing effects of
nicotine by modulating dopamine neuronal activity.
Nicotine is known to stimulate NE release in various brain regions including
cortex (Summers and Giacobini, 1995), hypothalamic paraventricular nucleus (PVN) (Fu
et al., 2001) and amygdala (AMG) (Fu et al., 2003). The studies from our laboratory
showed a positive correlation between the operant nicotine SA behavior and the
increment of NE release in the PVN and the AMG (Fu et al., 2001; Fu et al., 2003).
Additionally, nAChRs in the brainstem nucleus tractus solitarius (NTS) along with the
NMDA receptor and nitric oxide (NO) mediate the stimulatory effects of nicotine on NE
release in the PVN and the AMG (Fu et al., 1997; Zhao et al., 2007). Although few
studies provide a direct link between the NE system and the reinforcing effects of
nicotine, systemic administration of α2 adrenergic agonists, at doses shown to block
footshock-induced release of NE in the PFC and in the AMG, prevented the footshockinduced reinstatement of cocaine seeking but not cocaine-priming induced reinstatement.
This suggests that the NE system may play a role in stress-induced reinstatement, perhaps
through amygdaloid mechanisms (Erb et al., 2000; Kalivas and McFarland, 2003).
Studies have suggested that serotonin (5-HT) may be involved in the reinforcing
effects of nicotine. A low dose of nicotine (1µM) was perfused locally via a microdialysis
probe into several brain areas, resulting in a decrease in 5-HT levels in the hippocampus
(Hippo) and the VTA, and an increase in 5-HT levels in the AMG (Shearman et al.,
2005). Chronic nicotine administration (3 or 12 mg/kg/day) for 21 days increased tissue
5-HT levels in the frontal cortex and decreased levels in the hypothalamus (Kirch et al.,
1987). Prenatal nicotine exposure was implicated in changing serotoninergic
neurotransmission, which was evident during adolescence (Slotkin et al., 2006). Although
5-HT3 and 5-HT1A receptors do not seem to be involved in nicotine SA, as shown by the
selective 5-HT3 antagonists, ICS205-930 and MDL 72222, and the 5-HT1A agonist,
ipsapirone (Corrigall and Coen, 1994; Mosner et al., 1997), the 5-HT2C receptor
antagonist, RO 60-0178, attenuated the maintenance of nicotine SA in rats (Grottick et
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al., 2001), indicating that specific serotonergic receptor subtypes might be involved in
nicotine SA.
Several lines of evidence indicate that the opioid system might be involved in
nicotine SA. First, a high density of µ opioid receptors has been identified in the NAcc
(Tempel and Zukin, 1987). Second, systemic nicotine has been shown to elevate tissue
levels of opioid peptides in the NAcc (Pierzchala et al., 1987; Houdi et al., 1991). Third,
nicotine can release endogeneous opioid peptides (Davenport et al., 1990). The results
obtained from a series of neuropharmacological studies revealed the differential
involvement of opioid receptors in a region-specific manner. Naltrexone (0.1-10 mg/kg,
s.c.), administered 20 min prior to the start of nicotine SA, had no effect on nicotine SA
(Corrigall and Coen, 1991). However, at the highest dose (dose range: 0.005-0.05 µg), an
intra-tegmental infusion of the selective µ opioid receptor agonist, DAMGO, affected
nicotine SA. Additionally, an intra- PPTg infusion of DAMGO reduced nicotine SA
(Corrigall et al., 2002).
1.2.3. Neuroadaptive changes induced by nicotine SA and withdrawal
Nicotine activates and desensitizes nAChRs rapidly (Mansvelder and McGehee,
2000), but enhanced DA release by nicotine is sustained for up to two hours (Imperato et
al., 1986; Di Chiara and Imperato, 1988). Following extinction, three forms of
reinstatement have been described: cue-induced, stress-induced and drug-priming
injection-induced reinstatement (Shaham et al., 2003). After extinction of nicotine
seeking behavior, presentation of nicotine-associated stimuli (e.g. cue light) or the
delivery of a stressor (e.g., intermittent footshock) is able to reinstate nicotine seeking
behavior (Buczek et al., 1999; Liu et al., 2006). Prolonged neuroadaptive changes may
underlie the relapse to drug seeking behavior. For example, the up-regulation of the
cAMP pathway in the NAcc represents one key neuroadaptive change (Self and Nestler,
1998). Interestingly, it has been shown that modulating iGluR receptor expression
facilitates extinction, thus reducing the risk of relapse. Viral-mediated overexpression of
GluR1 and GluR2/3 receptors in the NAcc shell, which have been shown to be upregulated after extinction training, facilitates the extinction of cocaine seeking behavior
(Sutton et al., 2003). Furthermore, disruption of actin cycling has been shown to facilitate
cocaine-induced reinstatement of cocaine seeking behavior, indicating that neuroplastic
changes in actin cycling might contribute to reinstatement of drug seeking behavior
(Toda et al., 2006). In summary, multiple neuroadaptive changes might contribute to the
long-term effects of nicotine and other drugs of abuse, thereby predisposing to relapse.
Approximately 70% of adult smokers in the United States have tried to quit, but
these attempts are often unsuccessful due to the aversive aspects of the nicotine
withdrawal syndrome (Kenny and Markou, 2001). Experiments found that withdrawal
from chronic nicotine gradually reduced the nicotine-induced enhancement of NMDA
responsiveness in the CA1 region of hippocampus, which returned to baseline by day 8 of
withdrawal. This may underlie the cellular mechanism(s) of nicotine withdrawal
(Yamazaki et al., 2006). In addition, up-regulation of α7 receptors (the chronic nicotine
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control group did not show up-regulation) and reduced GABA release in the striatum was
observed in this withdrawal study, indicating neuroplastic changes in the glutamatergic,
cholinergic and GABAergic systems are involved during nicotine withdrawal (Yamazaki
et al., 2006). Taken together, these findings indicate that nicotine may induce
neuroadaptive changes during the exposure to nicotine and after withdrawal.
Nicotine has been shown to facilitate long term potentiation (LTP) of
glutamatergic inputs in the VTA (Mansvelder and McGehee, 2000). It is hypothesized
that α7 nAChRs and NMDA receptors have complementary roles in synaptic plasticity
because both receptors are highly permeable to Ca 2+ (Broide and Leslie, 1999).
Activation of presynaptic α7 nAchRs by nicotine in the VTA induces the influx of Ca 2+,
which in turn increases glutamate release. The increased glutamate release facilitates
activation of postsynaptic NMDA and non-NMDA receptors, which depolarize DA
neurons and contribute to the induction of LTP (Mansvelder and McGehee, 2000). In
addition, activation of postsynaptic nAChRs by nicotine also contributes to the induction
of LTP by removing Mg 2+ blockade of the postsynaptic NMDA receptors (Pidoplichko et
al., 1997). In this study, which utilized the concentration of nicotine present in a smokers’
blood after one cigarette, nicotine (0.5 µM) increased the spontaneous EPSC frequency
by approximately 2 fold in 90% of the neurons tested (Mansvelder and McGehee, 2000),
and this effect was blocked by selective α7 antagonist MLA, indicating a predominant
presynaptic mechanism underlying increased glutamate release by nicotine (Mansvelder
and McGehee, 2000). Moreover, pairing nicotine (1 µM) with postsynaptic
depolarization (200 stimulations at a frequency of 1Hz) increased the evoked EPSC
amplitude to 116% ± 2.3% of control for at least 40 min (Mansvelder and McGehee,
2000). Although the magnitude of this LTP was quite modest, the onset and duration
were consistent with LTP. This is the first paper to implicate nicotine in the induction of
long-term changes after a brief exposure.
Nicotine is also known to influence the structure of neurons (Robinson and Kolb,
2004). Repeated nicotine injections (0.7mg/kg) increased dendritic length and spine
density in the NAcc and the cingulate cortex (Brown and Kolb, 2001). This appears to be
a phenomenon common to other drugs of abuse, including cocaine, amphetamine and
morphine (Robinson and Kolb, 2004). Moreover, nicotine stimulated dendritic
arborization in the motor cortex (Gonzalez et al., 2005). However, since these
experiments were preformed under the condition of experimenter-administered (EA)
nicotine, the outcomes might be different with nicotine SA (Robinson and Kolb, 2004).
There have been very few papers that have examined neuroadaptation after
nicotine SA and withdrawal. Our lab has shown that nAChRs and ionotropic glutamate
receptors are altered by nicotine SA (Parker et al., 2004; Wang et al., 2007). During
nicotine SA, neuronal nAChRs in several brain regions were up-regulated, specifically,
α4, α6 and β2 (Parker et al., 2004). The up-regulation α4β2 by nicotine has been
reviewed (Buisson and Bertrand, 2002). This upregulation of surface α4β2 nAChRs has
been shown to reflect an increased rate of intracellular maturation (Sallette et al., 2005).
Under similar experimental conditions, after 18 days of nicotine SA, we have shown that
the levels of NMDA receptor subunit 2A (NR2A) and NR2B were increased by 67% and
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83% in the mPFC, respectively, and glutamate receptor subunit 2/3 (GluR2/3) was
increased by 34% in the VTA (Wang et al., 2007). However, the expression of ionotropic
glutamate receptors was not changed in the striatum (ST) and in the NAcc, indicating a
region-specific effect of nicotine SA (Wang, Chen et al., 2007). One study of dopamine
neurotransmission after early abstinence from limited access chronic nicotine SA (25
days) observed reduced basal dopamine levels in the nicotine treatment groups (both
nicotine SA and yoked nicotine group) compared to saline (Rahman et al., 2004). This
was due in part to increased DA reuptake after chronic nicotine treatment. The reduced
elevation of extracellular dopamine levels in the NAcc after nicotine injection indicated
that nAChR desensitization may occur early in abstinence after chronic nicotine (Rahman
et al., 2004). Overall, these observations provide clear evidence that neuroadaptive
changes take place during nicotine SA and withdrawal.

1.3. Neurotransmission in specific mesocorticolimbic regions
1.3.1. The functional role of glutamate system in the mPFC
Pyramidal neurons send glutamatergic projections to many subcortical regions
including the NAcc and the VTA. They also receive glutamatergic inputs as well as
GABAergic and dopaminergic inputs. Thus, the mPFC pyramidal neurons are highly
regulated. Many laboratories have reported that mPFC is critical in regulating various
behaviors during different phases of drug SA. These include the sensitization resulting
from repeated psychostimulant treatment (Wolf et al., 1995; Li and Wolf, 1997; Li et al.,
1999; Li et al., 1999) and reinstatement of cocaine seeking behavior (McFarland et al.,
2003). Additionally, mPFC contributes to general physiological responses such as to
restraint stress (Moghaddam, 1993; Jedema and Moghaddam, 1994).
Several studies have implicated mPFC glutamate in the development of
sensitization to psychostimulants. Ibotenic acid lesions of the PFC prevented the
development of sensitization of ambulatory hyperactivity, but not the sensitization of
stereotypy, after six repeated daily amphetamine treatments (Wolf et al., 1995). However,
this study did not differentiate the effects of these lesions on the acquisition vs.
expression of locomotor sensitization. In another study (Li and Wolf, 1997), lesioning the
PFC after the induction of sensitization failed to prevent the expression of sensitization to
amphetamine (Li and Wolf, 1997). A similar PFC lesion also prevented the induction of
cocaine sensitization (Li et al., 1999), but was unable to block the expression of cocaine
sensitization (Li et al., 1999). However, a specific lesion of dorsal mPFC, and not ventral
mPFC prevented expression of cocaine sensitization (Pierce et al., 1998). Consistent with
the idea that ventral and dorsal mPFC might have different roles in cocaine induced
behavioral sensitization, it has been found that excitotoxic lesions of prelimbic mPFC
regions, which provide dense projections to the VTA, blocked the induction of cocaine
sensitization (Tzschentke and Schmidt, 2000; Tzschentke and Schmidt, 2000) Taken
together, these studies demonstrate that the glutamate system in different regions of the
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mPFC is specifically involved in regulating the induction vs. expression of behavioral
sensitization to psychostimulants.
Recent data has shown that the mPFC glutamate system is involved in the
mechanisms whereby stress influences the reinstatement of drug seeking behavior.
Restraint stress induced a much larger increase of extracellular glutamate in the prefrontal
cortex than in the hippocampus and the basal ganglia (Moghaddam, 1993). Stressinduced mPFC dopamine release has been shown to be blocked by an AMPA/kainate
receptor antagonist (6-cyano-7-nitroquinoxaline-2,3-dione) administered into the mPFC
(Jedema and Moghaddam, 1994). Additionally, dopamine levels in the mPFC were
reduced upon blockade of mPFC AMPA receptors in the absence of stress (Takahata and
Moghaddam, 1998). Furthermore, inactivation of prelimbic mPFC by tetrodotoxin (TTX)
blocked both foot shock and cocaine-induced reinstatement of cocaine seeking behavior
(Capriles et al., 2003). However, infusion of the D1 receptor antagonist, SCH 22390 into
prelimbic mPFC, only blocked stress-induced but not cocaine-induced reinstatement
(Capriles et al., 2003). Taken together, these studies indicate that the glutamate system in
the mPFC is involved in regulating mPFC dopamine transmission under basal and stressinduced conditions, and in doing so, the mPFC glutamate system might contribute to the
stress-induced reinstatement of drug seeking (Takahata and Moghaddam, 1998; Capriles
et al., 2003).
It has been reported that glutamate and dopamine levels increased in the NAcc
core when extinguished cocaine SA behavior was reinstated by a cocaine-priming
injection (McFarland et al., 2003). Interestingly, dopamine levels increased when saline
control and cocaine-yoked rats were given a cocaine priming-injection (McFarland et al.,
2003). Moreover, the enhanced NAcc glutamate release was independent of lever
pressing. In the absence of a lever in the SA chamber during the reinstatement session,
animals displayed a time course of enhanced of glutamate release similar to a group of
animals with access to the lever (McFarland et al., 2003). Most importantly, inactivating
dorsal mPFC by microinjecting the GABAA receptor agonist, muscimol, and the GABAB
agonist, baclofen, blocked cocaine-priming induced reinstatement and glutamate release
in the NAcc core, indicating that dorsal mPFC glutamatergic projections to the NAcc
core play an important role in cocaine induced reinstatement of drug seeking behavior
(McFarland et al., 2003). On the other hand, blockade AMPA/kainate or NMDA
receptors in the NAcc core dose-dependently reduced cue-induced reinstatement of
cocaine seeking behavior (Backstrom and Hyytia, 2007), suggesting that dorsal mPFC
glutamatergic neurotransmission to NAcc core also might be involved in this form of
reinstatement.
1.3.2. The functional role of glutamate system in the VTA
GluR1 homomeric AMPA receptors are Ca2+ permeable, and Ca2+ is important in
initiating intracellular signaling cascades. Thus, drugs of abuse that upregulate GluR1
levels in the VTA might alter the membrane potential and intracellular signaling events
that contribute to sensitization (Carlezon and Nestler, 2002). It has been reported that rats
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that showed behavioral sensitization after repeated cocaine treatment had the highest
GluR1 levels in the VTA (Churchill et al., 1999). Consistent with the idea that upregulated GluR1 is associated with sensitization, chronic exposure to the D1 receptor
antagonist, SCH 23390, which has been shown to block behavior sensitization to
amphetamine (Vezina, 1996) and cocaine (Shippenberg and Heidbreder, 1995), reduced
GluR1 levels in the VTA (Carlezon and Nestler, 2002). Taken together, GluR1 in the
VTA might be involved in the cellular mechanisms underlying sensitization (Carlezon
and Nestler, 2002).
The glutamate system in the VTA has been shown to be critical in the reinforcing
effects of drugs of abuse. For example, blocking NMDA and AMPA receptors before a
cocaine conditioning trial abolished the induction of cocaine conditioned place preference
(CPP) (Harris and Aston-Jones, 2003). Heroin SA behavior was dose-dependently
blocked by intra-VTA administration of AP5 or ketamine, both of which are NMDA
receptor antagonists (Xi and Stein, 2002), indicating that NMDA receptors in VTA are
involved in the reinforcing effects of heroin SA as well.
Ionotropic glutamate receptors in the VTA are also thought to play an important
role in the reinstatement of drug seeking behavior. Bilateral perfusion of a nonselective
iGluR antagonist, kynurenate, attenuated stress-induced cocaine seeking behavior (Wang
et al., 2005). Moreover, blockade of ionotropic glutamate receptors by kynurenate dosedependently decreased cocaine-priming induced cocaine seeking behavior (Sun et al.,
2005).
The VTA glutamate system undergoes neuroadaptation during acute and chronic
treatment with drugs of abuse. Five drugs of abuse including amphetamine, cocaine,
morphine, ethanol and nicotine have been shown to enhance the AMPAR to NMDAR
EPSC ratio, suggesting an enhancement of AMPAR-mediated excitatory
neurotransmission in the VTA (Saal et al., 2003). As long as 90 days post-withdrawal
from cocaine SA, adaptation of ionotropic glutamate receptor expression has been
reported in the VTA. NR1 was up-regulated as late as 90 days post-withdrawal, while
GluR2 was up-regulated after only one day of withdrawal (Lu et al., 2003).
1.3.3. The effects of the mPFC on the VTA
In light of the above anatomical evidence for innervation between the mPFC and
the VTA, especially the glutamatergic projection from mPFC to VTA, functional studies
have revealed a critical role for these efferents in the regulation of VTA neuronal activity.
One of the major functions of this projection is to regulate the activity of dopamine
neurons in the VTA and the subsequent DA release of VTA afferent DA neurons,
although neuroanatomical studies indicate that this would be an indirect, polysynaptic
effect of mPFC glutamatergic projections –most likely to laterodorsal tegmental nucleus
(Omelchenko and Sesack, 2007).
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The firing pattern of DA neurons in the VTA has been examined extensively, and,
thus, complicated results have been reviewed and categorized into three groups
(Tzschentke, 2001). A fundamental observation pertaining to our study was obtained
from a midbrain slice preparation that demonstrated the firing rate of VTA dopamine
neurons was increased by glutamate, NMDA, AMPA, and kainate without changing the
burst firing activity (Seutin et al., 1990; Wang and French, 1993; Wang and French,
1993). Interestingly, when the VTA was perfused with NMDA through a microdialysis
probe, the regulation of DA release in the NAcc appeared to be biphasic: low dose
NMDA (<100µM) increased DA release in the NAcc, while high dose NMDA (>100µM)
decreased DA release. Furthermore, the DA release in the NAcc was strongly correlated
with the VTA DA neuron firing rate (Wang et al., 1994). This study suggested that
glutamatergic stimulation in the VTA was involved in regulating DA release in the NAcc
and DA neuron activity in the VTA. Direct bilateral stimulation of mPFC at intensities
which have been shown to support intracranial self stimulation (ICSS) increased DA
release by about 38% and 69% in the NAcc at 50µA and 100µA stimulus, respectively
(Taber and Fibiger, 1995). Application of AP5 and CNQX in the VTA blocked the
enhanced DA release in the NAcc during the cortical stimulation (Taber et al., 1995),
suggesting that the glutamatergic projections from mPFC regulate the activity of DA
neurons in the VTA possiblely through indirect, polysynaptic mPFC glutamatergic
projections (Omelchenko and Sesack, 2007).
By using antero- and retrograde tracers, it is known that glutamatergic projections
to the VTA are target-specific: PFC synaptic inputs selectively synapse on GABAcontaining mesoaccumbens neurons or DA-containing mesocortical neurons (Carr and
Sesack, 2000). Interestingly, a neurochemical study using in vivo microdialysis supported
this neuroanatomical observation. Intra-VTA reverse microdialysis of 100µM LY293558,
an AMPA/kainate antagonist, increased DA release in the NAcc by reducing the activity
of GABA interneurons and, thereby, disinhibiting mesoaccumbens VTA DA neurons. In
contrast, this compound reduced DA release in the PFC due to the inhibition of AMPA
receptors on mesocortical VTA DA neurons (Takahata and Moghaddam, 2000). This
observation suggests that mesocortical DA neurons are primarily under direct excitatory
control from mPFC glutatamatergic inputs, while mesoaccumbens DA neurons are also
affected indirectly by mPFC glutamatergic inputs to GABA interneurons (Takahata and
Moghaddam, 2000). Further experiments would be necessary to determine whether tonic
glutamatergic inputs differentially regulate VTA DA neurons or GABA interneurons in a
target specific manner, e.g. whether tonic glutamatergic inputs to mesocortical DA
neurons might be greater than to mesoaccumbens DA neurons or, alternatively, tonic
glutamatergic inputs to GABA interneurons regulating mesoaccumbens VTA DA
neurons might be greater than to those regulating mesocortical VTA DA neurons.

1.4. Self-administration model in nicotine abuse
Nicotine has been shown to be self-administered by several animal species,
including primates (Goldberg, Spealman et al., 1981), dogs (Risner and Goldberg, 1983)
and rodents (Corrigall and Coen, 1989; Valentine et al., 1997). The significance of these
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animal models of nicotine self-administration can be addressed in four ways: first, the
fact that nicotine is self-administered by multiple species indicates that nicotine is a
reinforcer (Corrigall, 1999); second, these are valid models for the pre-clinical testing of
medication because of the obvious parallels between the human smoking behavior and
animal self-administration (Corrigall, 1999); third, these models can be used to examine
the motivational effects of nicotine, which are difficult to study in human subjects
because of ethical concerns (Corrigall, 1999); fourth, these models can contribute to
understanding the neuronal and neurochemical mediators of nicotine dependence
(Corrigall, 1999).
The majority of studies of nicotine self-administration have utilized the
intravenous route, since oral self-administration does not emulate the pharmacokinetics
of smoking, which has a very rapid uptake of nicotine into the circulation and rapid
delivery to the brain. In essence, intravenous nicotine self-administration is the best
nicotine self-administration model available for studying the motivational circuits
involved in the behavioral effects of nicotine. Besides recognizing the research value of
this animal model, we acknowledge that there are also differences between animal
models of nicotine SA and human smoking behavior. For example, the intravenous route
versus inhalation of tobacco smoke (Rose and Corrigall, 1997) lacks the rich sensorymotor stimulation of the respiratory tract and the aroma of the smoke. These appear to
make significant contributions to the reinforcing efficacy of nicotine.
Based on the schedule of access to nicotine, there are two models of intravenous
nicotine self-administration: intermittent access and unlimited access models. Intermittent
access has the advantage of relatively higher response rates per hour for nicotine because
of the relatively short session time, which is useful in examining the effects of a short
acting drug on nicotine SA within a limited time interval. It does not, however, emulate
the unrestricted nature of human smoking behavior insofar as humans have relatively
unlimited access to nicotine in cigarettes. The first unlimited access model was developed
in 1979 by the Hanson group (Hanson et al., 1979). In their model, rats were pretreated
with various doses of nicotine ranging from 0 to 0.06mg/kg/infusion every 30 minutes
over 48 hours (Hanson et al., 1979). Then, animals were allowed to self-administer
nicotine at the same dose that they had previously received and with 24 hour unlimited
access at an FR1 reinforcement schedule, in which each lever press results in the delivery
of one nicotine infusion (Hanson et al., 1979). They found that nicotine-maintained
responding was greater than saline control and dose dependent with the peak response at
0.03mg/kg/dose, which is the dose we used in the dissertation work. However, the
pretreatment also complicated the interpretation of the reinforcing effect of nicotine. In
another unlimited access schedule study but without nicotine pretreatment, nicotine was
self-administered at several doses, particularly at 0.03mg/kg dose (Cox et al., 1984).
However, the rate of responding on the inactive lever was high and dose-dependent.
Thus, the specificity of this operant behavior was not established in these studies (Cox et
al., 1984).
Our laboratory reported a revised procedure of unlimited access to nicotine selfadministration (Valentine et al., 1997), showing that rats individually housed in operant
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chambers were able to acquire nicotine self-administration at doses as low as
0.00375mg/kg per infusion without previous training, shaping or food deprivation
(Valentine et al., 1997). Moreover, the nicotine intake of rats ranged from 0.18 to 1.38
mg/kg, which is similar to the quantities self-administered by humans (Valentine et al.,
1997). Furthermore, our laboratory examined the effects of rat strain differences on
nicotine self-administration behavior. Inbred Lewis rats were more susceptible to nicotine
SA than Sprague- Dawley or Fisher 344 rats (Brower et al., 2002); based on this study,
male Lewis rats are the subjects of this dissertation research project. Thus, my
dissertation work utilized addiction prone Lewis rats in our established model of
unlimited access to nicotine self-administration in order to emulate nicotine selfadministration in humans who might be genetically susceptible to becoming dependent
on the drug.

1.5. Summary
Despite the intensification of efforts to reduce smoking, nicotine abuse and
addiction through cigarette smoking is still the leading preventable cause of death in the
United States. Accumulating data implicates the mesocorticolimbic system in mediating
the reinforcing effects of drugs of abuse. Multiple neurotransmitter systems within the
mesocorticolimbic system including dopamine, glutamate, GABA and serotonin have
been shown to be involved. The mesocorticolimbic system undergoes robust
neuroadaptation during acute as well as chronic nicotine treatment and post-withdrawal.
mPFC and VTA are two critical neuroanatomical regions within the mesocorticolimbic
system. The mPFC provides the primary excitatory inputs to subcortical areas including
the NAcc and the VTA, while VTA DA neurons project to NAcc and mPFC as well.
Thus, the mPFC and VTA are functionally connected and reciprocally regulated. Several
drugs of abuse induce neuroadaptive changes in the glutamate circuitry within the mPFC
and the VTA. It has been hypothesized that the glutamate system in the VTA is important
for the induction of cocaine sensitization while the glutamate system in the mPFC is
important for the expression of cocaine sensitization. In contrast, it is unclear what roles
the glutamatergic projections from mPFC to the VTA play during chronic nicotine SA
and post-withdrawal. It has been shown that the VTA glutamate system is critical in
mediating the reinforcing effects of drugs of abuse. Thus, the firing pattern of dopamine
neurons in the VTA, which are critical to the acquisition of operant drug selfadministration, can be regulated by glutamatergic inputs. Utilization of a chronic nicotine
self-administration model enables us to emulate human nicotine intake behavior in rats.
The long-term changes in the mesocorticolimbic glutamate system that occur with
chronic nicotine SA have not been reported. Thus, this dissertation focuses on
neuroadaptive changes in the glutamate pathways within the mesocorticolimbic sytem
during chronic nicotine SA and post-withdrawal.
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1.6. Specific aims
In light of the studies described above, the mesocorticolimbic pathway is critical
in almost all aspects of drug abuse. Pyramidal neurons in the mPFC project glutamatergic
fibers to the VTA and, in turn, receive dopaminergic inputs from the VTA. Though many
of the neurochemical and molecular effects of nicotine have been well studied, the drug’s
long-term neuroadaptive effects, specifically within the mesocorticolimbic pathway, are
largely undefined. A series of experiments have been designed to investigate: (1) the
molecular neuroadaptive changes in ionotropic glutamate receptors during chronic
nicotine self-administration and post-withdrawal; and (2) the neurochemical and
behavioral changes that might result from these receptor changes. The working
hypothesis of this dissertation is that there exists a hyperglutamatergic state of
neurotransmission between the mPFC and VTA during chronic nicotine SA. The
following are the Specific Aims of this project, which were examined in Chapters 2 and
3:
•
•

To determine the changes in the expression of ionotropic glutamate receptors
within the mesocorticolimbic pathway during chronic nicotine self-administration.
To investigate the neurochemical as well as behavioral changes associated with
these alterations in receptor expression during chronic nicotine SA and postwithdrawal.
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Chapter 2. Selective Up-Regulation of Ionotropic
Glutamate Receptor Subunits within Mesocorticolimbic
Regions during Chronic Nicotine Self-administration*
2.1. Introduction
The mesocorticolimbic system, which is involved in cognition, stress, and goaldirected motor activity, as well as addiction, involves the ventral tegmental area (VTA),
nucleus accumbens (NAcc), prefrontal cortex (PFC), striatum (ST), hippocampus, and
amygdala (Le Moal and Simon, 1991). Nicotine, the major psychoactive component of
cigarette smoke, has been shown to stimulate mesocorticolimbic dopamine pathways,
which originate in the VTA, resulting in dopamine (DA) secretion within the NAcc and
PFC (Corrigall et al., 1992). In so doing, nicotine activates various subtypes of nicotinic
cholinergic receptors (nAChRs) located on dopaminergic neurons, GABAergic neurons,
and glutamatergic terminals within the VTA, and on dopamine terminals in the projection
regions (e.g. NAcc) (Corrigall et al., 1992). This nicotinic stimulation of dopamine
secretion is essential for the reinforcing effects of nicotine (Corrigall et al., 1992).
However, other neurotransmitter pathways, such as glutamatergic neurons projecting
from PFC to VTA, also are involved in the motivational effects of nicotine (Watkins et
al., 2000; Picciotto and Corrigall, 2002).
Synaptic glutamate binds to N-methyl-D-aspartate (NMDA) and α-amino-3hydroxy-5-methyl-4-isoxazole propionic acid (AMPA) receptors, opening postsynaptic
cation channels that mediate fast excitatory neurotransmission (Nakanishi et al., 1998).
Recent reports have shown that nicotine stimulated VTA glutamate release through
presynaptic nicotinic acetylcholine receptors, which in turn excited VTA dopaminergic
neurons (Fu et al., 2000; Mansvelder and McGehee, 2000). Nicotine induced glutamate
release through α7 subunit-containing nAChRs on glutamate terminals in a VTA slice
preparation (Mansvelder and McGehee, 2000). Ultrastructural and in vivo microdialysis
studies support the idea that the excitation of VTA dopamine neurons is primarily
dependent on glutamatergic efferents from PFC (Sesack and Pickel, 1992; Taber et al.,
1995). Using in vivo microdialysis, our lab also showed that nicotine dose-dependently
stimulated DA release in NAcc, an effect that was abolished by infusing NMDA
antagonists (AP-5 or CGS 19755) into VTA (Fu et al., 2000). These findings demonstrate
the pivotal role played by glutamatergic pathways in the excitation of mesocorticolimbic
dopaminergic neurons by nicotine.
____________________________________
* Chapter 2 reprinted by permission of the publisher: Wang, F., Chen, H., Steketee, J.D.
and Sharp, B.M. (2007) Upregulation of ionotropic glutamate receptor subunits within
specific mesocorticolimbic regions during chronic nicotine self-administration.
Neuropsychopharmacology, 32, 103-9.
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Nicotine, like other drugs of abuse, elevated the ratio of AMPA/NMDA
excitatory post-synaptic currents (EPSC) in midbrain dopamine neurons, consistent with
enhanced dopaminergic neurotransmission (Saal et al., 2003). Nicotine also enhanced
NMDA and/or AMPA-induced synaptosomal release of norepinephrine from the
hippocampus and dopamine from the striatum (Risso et al., 2004). These functional
studies suggest that nicotine may up-regulate ionotropic glutamate receptors but do not
provide insight into the effects of nicotine on the actual expression of ionotropic
glutamate receptors in specific brain regions. The expression of GluR1 mRNA in VTA
has been found to be increased after acute injection of nicotine directly into VTA (Ferrari
et al., 2002). However, the effects of chronic nicotine self-administration on ionotropic
glutamate receptor protein levels have not, to our knowledge, been studied. The aim of
this study was to determine whether chronic nicotine self-administration modulates
protein levels of ionotropic glutamate receptor subtypes within mesocorticolimbic
regions. To accomplish this, Western blotting with subunit specific antibodies was used
to obtain semi-quantitative comparisons within the VTA, PFC, NAcc and ST.

2.2. Materials and methods
2.2.1. Materials
(-)-Nicotine hydrogen tartrate (all doses calculated as free base) was purchased
from Sigma (St. Louis, MO). Operant chambers, circuit boards, interface modules and SA
software were from Coulbourn Instruments (Allentown, PA).
2.2.2. Nicotine self-administration
Self-administration was performed according to our previously published protocol
with minor modifications (Valentine et al., 1997). Seven days after acclimation to a
reverse light cycle and handling, male Lewis rats (Harlan Sprague Dawley, Indianapolis,
IN), weighing 250-350g, received jugular cannulae under xylazine-ketamine anesthesia
(13 and 87 mg/kg, i.m., b.wt., respectively; Parke-Davis, Morris Plains, NJ) and then
were immediately placed into individual operant chambers where they resided for the
duration of the study. Rats were allowed to recover for 3 d, during which time they
received hourly injections of heparin (100-200 U/ml in 50 µl) and a daily injection of the
antibiotic Baytril (7.6 mg/kg in 0.1 ml, i.v.; Bayer Corp., Shawnee Mission, KS). Then
rats were randomly assigned to treatment groups and jugular lines were filled with either
0.03 mg/kg nicotine in 200 U/ml heparinized saline (50 µl delivered over 0.81 sec per
300 gm body weight) or heparinized saline alone. The nicotine solution was freshly
prepared every 7-14 day and stored in a foil-wrapped glass bottle at 4°C. Every day, the
nicotine solution remaining in the syringe was discarded and the syringe was refilled.
Each sound-attenuating environmental enclosure was equipped with its own
ventilation fan and house light; the light was scheduled to turn off daily at exactly 10:30
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A.M. and on again at 10:30 P.M. The interior operant chamber contained two levers
positioned 5 cm above the floor and a green cue light 1 cm above each that signaled the
availability of nicotine. One lever was randomly assigned as the active bar and would
signal the computer-driven pump to deliver a 50 µl/ 0.81 sec bolus injection of nicotine or
saline when pressed by the rat; pressing the other bar had no consequence. Injections were
followed by a 7 sec time-out, during which the green light above the active bar was not
illuminated and nicotine or saline were unavailable. Rats were not shaped, conditioned, or
food deprived in preparation for lever pressing and were allowed to acquire selfadministration behavior throughout the 23 hr.
Environmental enclosures, operant chambers, and syringe pumps were controlled
by Coulbourn Habitest Universal LabLink interfaces and computers located in an
adjacent room. Each morning, during the final hour of the lights-on cycle (i.e., at 9:30
A.M.), the clock for the computer program (Coulbourn L2T2) had to be manually reset,
necessitating a short interruption in nicotine availability. To accommodate this, as well as
to accomplish animal husbandry needs, measurements of body weight, and data
downloading, all of the environmental enclosures were opened and the green cue lights
were turned off to signal this interruption to the rats. Levers were not retracted, and lever
press activity was not recorded. Exactly 1 h later (10:30 A.M.), house lights were
switched off, cue lights were illuminated, nicotine (or saline) was again available, and
enclosure doors were shut. All procedures were conducted in accordance with the NIH
Guidelines Concerning the Care and Use of Laboratory Animals and were approved by
the Animal Care and Use Committee of the University of Tennessee.
Rats were housed in self-administration chamber for 18 days. By day 8, stable
nicotine self-administration had been achieved in that active lever presses were two-fold
greater than inactive in each animal. All animals continued to self-administer nicotine
until day 18.
2.2.3. Brain punches and tissue preparation
On day 19, after rats had access to nicotine for 4 h, they were anesthetized with
isoflurane and decapitated. The average time interval between the last active lever press
for nicotine and removal of the animals from operant chambers was 31.8 min; thus, rats
were untethered from their chambers 3h and 28.2± 18.6 min (mean± SD) after the start of
the session. Rat brains were removed and stored at –80°C. Frozen brain sections of 0.7
mm thickness were obtained using arrays of 20 double-edge razor blades (Professional
Medical Products Inc. Greenwood, SC), designed and constructed in our laboratory. The
blade arrays were assembled using two screws with matching wing-nuts. One 0.7 mm
stainless steel washer per screw (Small Parts, Inc. Miami Lakes, FL) was used to separate
each blade. Brains were first equilibrated at -20°C for 10 min. The ventral surface of the
brain was then placed on top of the blade array and was gently and briefly pressed
downward. Care was taken to ensure the rostral-caudal axis of the brain was
perpendicular to the blades (for coronal sections). The brain and the blades then were
turned upside down and set on top of a cold (-10°C) metal plate (FTS systems, Stone
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Ridge, NY). Using a slight rocking motion, a metal block was applied to gradually press
the entire brain into the blades, insuring that the brain was completely embedded within
the blades. The assembly then was disassembled on powdered dry ice, and individual
brain slices were laid flat on a cold (-10°C) surface. Brain areas of interest were identified
with a dissecting microscope, according to the atlas of Paxinos and Watson (1986), and
punched out using a 20-gauge syringe adapter. Excised tissue was immediately
transferred to tubes embedded in dry ice and stored at -80 °C until further processing.
Dissected tissues were sonicated in 2% sodium dodecyl sulfate (SDS) solution for 30 sec
in an ice water bath. Sonicated tissues were centrifuged at 800 × g, 5 min. Protein
concentrations were measured using the bicinchoninic acid assay (Pierce, Rockford, IL)
with bovine serum albumin (BSA) as the standard.
2.2.4. Western blotting
To determine ionotropic glutamate receptor expression level differences after
treatment, samples of the same brain region from both treatment groups (nicotine vs.
saline) were loaded in alternating sequence on the same gel.
Samples were diluted in Laemmli buffer (Bio-Rad, Hercules, CA) at a ratio of
1:2, and were boiled for 5 min., loaded, and then separated on 10% polyacrylamide gels
in a buffer containing 0.1% SDS, 192 mM glycine, and 25 mM Tris, pH 8.3. Proteins
were then transferred to polyvinylidene difluoride membranes (Bio-Rad, Hercules, CA)
in a buffer containing 192 mM glycine, 20% methanol and 25 mM Tris, pH 8.3 at 4°C
overnight. After transfer, membranes were washed in Tris- buffered saline with Tween20 (TBST; 100 mM Tris and 0.9% sodium chloride with 0.1% Tween 20). Membranes
were blocked with agitation by 5% non-fat dried milk for 2 hours at room temperature
(RT). Based on the molecular weight differences between NMDA subunits, AMPA
subunits, and β-actin, blots were carefully cut into three separate sections by visualizing
the protein molecular weight markers: upper blots were used to detect NMDA receptor
subunits, middle blots to detect AMPA receptor subunits, and lower blots to detect βactin in order to evaluate protein loading. These blots were incubated with selective
antibodies against β-actin (1:1000; Sigma, St. Louis, MO), glutamate receptor subunit 1
(GluR1; 1:1000;Upstate, Lake Placid, NY), GluR2/3 (1:1000; Upstate, Lake Placid, NY),
NMDA receptor subunit 1 (NR1; 1:400; Santa Cruz, CA), NR2A (1:200; Santa Cruz,
CA), and NR2B (1:500; Upstate, Lake Placid, NY). Blots were then washed in TBST and
incubated in horseradish peroxidase-conjugated secondary antibodies (1:3000 for β-actin,
1:1500 for detecting the others). All antibodies were diluted in the same blocking solution
and incubated for 2hr RT or overnight at 4°C. Target proteins were visualized by
Supersignal (Pierce, Rockford, IL) followed by imaging using a Bio-Rad ChemiDoc
instrument with quantitation by Quantity One software (Bio-Rad, Hercules, CA).
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2.2.5. Data analysis
To determine the specificity of nicotine self-administration, the number of active
versus inactive lever presses per day was compared within each treatment group (i.e.,
nicotine and saline). Data are presented as mean ± S.E.M. Comparisons of active versus
inactive lever presses within treatment groups were made by two-way analysis of
variance, using SPSS statistical software, version 12.0 (SPSS Inc., Chicago, IL).
Each sample from a rat was run once on each of two gels. Optical density values
for each lane were normalized to β-actin to control for variation in loading and transfer.
For each sample, normalized values that had been averaged between the two blots were
used to conduct statistical comparisons (independent samples t-test) to identify treatment
effects within a region for each subunit. The mean values of nicotine treatment groups
were expressed as a percentage of saline ± S.E.M. Treatment differences were considered
significant at p< 0.05.

2.3. Results
2.3.1. Nicotine self-administration
The numbers of daily active vs. inactive lever presses (mean ± S.E.M.) are
presented in Figure 2.1. In the nicotine treatment group, the mean level of active lever
presses by rats receiving a programmed injection of i.v. nicotine immediately after each
active lever press was approximately twice the inactive presses. In this group, active lever
presses were significantly higher than inactive (F1,10= 51.49, p<0.001), whereas no
difference was observed in the saline group (F1,10= 3.68, p>0.05). A comparison of active
lever presses in the nicotine vs saline groups also showed a significant treatment effect
(F= 9.57, p= 0.002).
2.3.2. Chronic nicotine self-administration-induced up-regulation of NMDA and
AMPA receptor subtypes within mesocorticolimbic regions
In all immunoblots, only one band was visualized. Representative gels from each
group are shown in Figures 2.2-2.5. NMDA receptor NR2A and NR2B subunits were
visualized at a molecular weight of 180 kDa. Chronic nicotine SA significantly increased
NR2A and NR2B subunit expression levels in PFC by 67% (p= 0.04) and 83% (p=
0.027), respectively (Figure 2.2). The GluR2/3 subunit was visualized at 110 kDa. In
VTA, chronic nicotine SA preferentially up-regulated the GluR2/3 receptor expression
level by 34% (p= 0.011; Figure 2.3). In contrast, Figures 2.4 and 2.5 show that NAcc and
striatal NMDA and AMPA receptor subunit levels were unaffected by chronic nicotine
SA.
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Figure 2.1. Lever-pressing activity during 18 days of nicotine (Nic) selfadministration compared to saline (Sal). The mean numbers (± S.E.M.) of lever
presses (active or inactive) per day for the four data sets were analyzed by two-way
analysis of variance. In the nicotine group, the difference between active vs. inactive
lever presses was significant (F = 38.79, p = 0.002; n= 7), but not in the saline group (F=
0.53, p >0.05; n= 6). Brain tissues from these animals were used in the immunoblots
shown in Figures 2.2-2.5.
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Figure 2.2. Nicotine self-administration (18 days) up-regulated NR2A and NR2B
subunit levels within the prefrontal cortex (PFC) of rat brain. Nicotine induced
significant increases (67% and 83%) in NR2A and NR2B subunit immunoreactivities
within the PFC. Data were normalized to β-actin levels and converted to mean percent of
saline ± S.E.M. for each subunit (nicotine n= 7, saline n= 6). Representative blots
comparing saline (S) vs nicotine (N) treated animals are shown for each subunit. *,
significantly different from saline; p < 0.05, unpaired t-test.
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Figure 2.3. Nicotine self-administration (18 days) increased GluR2/3 subunit
immunoreactivity within the ventral tegmental area (VTA) of rat brain. Nicotine
increased GluR2/3 subunit levels in this region by 34% (nicotine n= 7, saline n= 6).
Representative blots comparing saline (S) vs nicotine (N) treated animals are shown for
each subunit. *, significantly different from saline; p < 0.05, unpaired t-test.
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Figure 2.4. Nicotine self-administration (18 days) produced no statistically
significant alterations in any of the subunits within the nucleus accumbens (NAcc)
shell of rat brain. Representative blots comparing saline (S) vs nicotine (N) treated
animals are shown for each subunit (nicotine n= 7, saline n= 6).
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Figure 2.5. Nicotine self-administration (18 days) produced no statistically
significant alterations in any of the subunits within the striatum (ST) of rat brain.
Representative blots comparing saline (S) vs nicotine (N) treated animals are shown for
each subunit (nicotine n= 7, saline n= 6).

28

The relatively large variance in NR2A levels in NAcc (Figure 2.4) and the
statistical tendency toward a difference between treatment groups (p= 0.06) prompted a
second experiment. NR2A was unaffected by nicotine SA (immuno- blot optical density,
expressed as a percentage of the saline group: 100± 12.6 vs 109.6± 27.5% (values are
mean± SEM) for saline vs nicotine, respectively; p>0.05, n= 6 per treatment group). For
comparison, NR1 determinations were also repeated. As previously reported, no
treatment effects were found (100± 5.5 vs 99.8± 21.1% for saline vs nicotine,
respectively; p> 0.05, n= 6 per treatment group).

2.4. Discussion
In rats chronically self-administering nicotine, several glutamate receptor subunits
were up-regulated within the mesocorticolimbic pathway. These include NR2A and
NR2B receptor subunits within PFC and GluR2/3 subunits within VTA. These findings
demonstrate that chronic nicotine SA selectively modulates ionotropic glutamate receptor
subunit expression levels, suggesting that glutamatergic neurotransmission is altered
within the mesocorticolimbic pathway.
One study determined the response of ionotropic glutamate receptor mRNA
levels, but not protein subunits, to chronic treatment with nicotine in vivo. It indicated
that chronic nicotine exposure during postnatal days 8- 12 significantly increased NR2A
mRNA levels in auditory cortex, whereas thalamic NR2B mRNA levels declined (Hsieh
et al., 2002). This finding suggests that chronic exposure to nicotine affects the
transcription of specific ionotropic glutamate receptor subunits in certain brain regions.
However, subunit expression was only studied during the period of rat postnatal brain
maturation equivalent to the third trimester of human brain development.
Several drugs of abuse have been shown to impact the function of ionotropic
glutamate receptors. A recent study suggested that glutamatergic neurotransmission was
altered after a single exposure to several drugs of abuse (Saal et al., 2003). In that study,
24- 30 h after in vivo exposure (i.p. injection) to nicotine, morphine, ethanol, cocaine or
amphetamine, the strength of excitatory synapses on dopamine neurons was enhanced,
reflecting an increase of AMPA/NMDA EPSC (Saal et al., 2003). However, the
molecular mechanism(s) underlying these synaptic effects on midbrain dopamine neurons
was not identified. The time interval between drug exposure and the detection of
increased synaptic strength was probably sufficient for increased ionotropic glutamate
subunit expression to have occurred.
One may postulate that chronic exposure to abused drugs can induce an increase
in AMPA receptor subunit expression. This is supported by experiments showing that
chronic cocaine treatment up-regulated GluR1 and NR1 subunit levels in VTA, and that
escalating doses of morphine also enhanced the expression of GluR1 subunits in VTA
(Fitzgerald et al., 1996). In addition, after 3 days of withdrawal from repeated
administration of cocaine or amphetamine, the direct application of AMPA onto VTA
dopamine neurons resulted in increased glutamate responsiveness of these neurons
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(Zhang et al., 1997). Consistent with these findings, in the current study, chronic nicotine
SA increased GluR2/3 subunit levels by 30% in VTA. This finding suggests that there
might be a larger pool of recycling GluR2/3 subunits in VTA neurons since these
subunits are known to recycle constitutively, which is important for the maintenance of
basal synaptic activity (Passafaro et al., 2001; Shi et al., 2001). We also speculate that the
AMPA/NMDA EPSC ratio may be increased if more GluR2/3 subunits reside in the
plasma membrane. Interestingly, immunocytochemical studies have shown that GluR2/3
subunits were found in 63% of tyrosine hydroxylase (TH)- positive VTA neurons,
whereas GluR1 subunits were in 20% (Chen et al., 2001). Thus, the up-regulated
GluR2/3 subunits induced by chronic nicotine SA might be present in ‘silent synapses’,
which had no AMPA receptors prior to nicotine SA, and in the GluR1/TH doublepositive neurons, as well as GABAergic interneurons within VTA.
All drugs of abuse appear to enhance dopamine secretion in the NAcc (Berridge
and Robinson, 1998). Nicotine does so in part through presynaptic α7 subunit-containing
nicotinic receptors, located on glutamatergic terminals, which synapse on dopaminergic
neurons within VTA (Mansvelder and McGehee, 2000). Nicotine stimulates glutamate
release, increasing dopaminergic neurotransmission (Mansvelder and McGehee, 2000).
Since the primary excitatory inputs to VTA originate in the PFC (Picciotto and Corrigall,
2002), enhanced excitatory input based on PFC- dependent mechanisms also may be a
factor. We found that PFC NR2A and NR2B subunit levels were up-regulated by
approximately 67% and 83%, respectively, after nicotine SA. As the dendrites and soma
of PFC glutamatergic neurons, which project to VTA, themselves receive glutamatergic
inputs (Steketee, 2003), it is conceivable that the increased expression of PFC NMDA
receptors containing NR2A and NR2B enhance the excitatory glutamatergic input to
VTA. Similarly, a previous study found that chronic ethanol exposure increased NMDA
(i.e., NR1, NR2A and NR2B) and AMPA (i.e., GluR2/3) receptor subunit levels in
primary cortical cultures, suggesting that increased activity of PFC glutamatergic neurons
may be a mechanism common to multiple drugs of abuse (Chandler et al., 1999).
Previous studies indicate that availability of NR2 subunits may be a limiting
variable in the expression of intact NMDA receptors on the plasma membrane, as about
50% of NR1 is located in cytoplasmic pools while approximately 90% of NR2B is
located at the cell surface (Hall and Soderling, 1997). Although the NR2B subunit
appears to be constitutively trafficked to the synapse, NR2A overexpresson leads to its
synaptic incorporation in an activity- dependent manner (Barria and Malinow, 2002).
Collectively, theses observations suggest that the nicotine SA- induced increase in PFC
NR2A and 2B are likely to be incorporated in functional NMDA receptors.
Compared with VTA, NAcc may be less sensitive to the excitatory effects of
glutamate, as evident in single cell recordings in vivo, made on the fifth day of treatment
with cocaine or amphetamine (White et al., 1995). The overall current response of VTA
dopamine neurons to glutamate was significantly elevated in amphetamine and cocaine
treated rats, whereas this was not observed in NAcc neurons (White et al., 1995).
Consistent with this, we did not observe significant changes in the expression of either
NMDA or AMPA receptor subunits in the dopamine terminal regions (e.g., NAcc and
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ST) of animals chronically self-administering nicotine; NR2A showed only a tendency to
increase in NAcc. This indicates the regional specificity of the changes in glutamate
receptor subunit expression induced by chronic nicotine SA. Although these regional
changes in glutamate receptor subunit expression may impact neuronal function, perhaps
underlying alterations in the glutamatergic responsiveness of VTA dopamine neurons
exposed to drugs of abuse, additional studies beyond Western immunoblotting are
necessary to elucidate the implications of the present findings. Furthermore, other
adaptive changes (e.g., post-translational changes such as phosphorylation) may occur in
some regions where protein levels were unaffected (White et al., 1995).
To our knowledge, this is the first report of altered ionotropic glutamate receptor
subunit expression during chronic nicotine SA. Based on these findings, we hypothesize
that there exists a hyperglutamatergic state within the mesocorticolimbic pathway during
chronic nicotine SA (Kalivas, 2004). This may be involved in aspects of drug SA, such as
sensitization, that reflect the occurrence of increasing neuronal plasticity with duration of
exposure (Wolf et al., 2004). Further investigation will be needed to evaluate the
neurochemical changes underlying this hypothesis. In summary, chronic nicotine SA
selectively up-regulated NR2A and NR2B receptor subunits in PFC and GluR2/3 subunit
in VTA. These findings may implicate hyperglutamatergic neurotransmission within the
mesocorticolimbic dopaminergic circuitry.
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Chapter 3. Neuroadaptive Changes in the Mesocortical
Glutamatergic System during Chronic Nicotine SelfAdministration and after Extinction in Rats
3.1. Introduction
Drug abuse is associated with molecular and cellular neuroadaptation within the
mesocorticolimbic system (Koob, 1992; Nestler, 1992; Hyman et al., 2006). This system
includes the medial prefrontal cortx (mPFC), which provides the primary glutamatergic
excitatory input to subcortical areas such as the nucleus accumbens (NAcc) and ventral
tegmental area (VTA), and the VTA whose dopaminergic efferents regulate NAcc
medium spiny neurons and mPFC pyramidal neurons (Sesack and Pickel, 1992; Taber et
al., 1995; Omelchenko and Sesack, 2007). mPFC is instrumental to many dimensions of
drug abuse including the expression of behavioral sensitization to psychostimulants
(Wolf et al., 1995; Li and Wolf, 1997; Li et al., 1999; Li et al., 1999) and drug-primed
reinstatement of drug-seeking behavior (McFarland et al., 2003). Within the mPFC and
VTA, glutamatergic neurotransmission adapts to nicotine, reflecting changes in the
expression and function of nicotinic acetylcholine receptors (nAChRs) and ionotropic
glutamate receptors (iGluRs) (Mansvelder and McGehee, 2000; Mansvelder and
McGehee, 2002; Saal et al., 2003; Wang et al., 2007).
Nicotine activates VTA nAChRs that stimulate dopamine release in the NAcc,
which is essential for nicotine self-administration (SA) (Corrigall et al., 1992).
Glutamatergic efferents from mPFC have an important role in the regulation of NAcc
dopamine (DA) levels (Sesack and Pickel, 1992; Taber et al., 1995). For example,
blockade of ionotropic glutamate receptors in the VTA, decreased basal NAcc dopamine
by 30% and blocked DA release evoked by mPFC stimulation (Taber et al., 1995).
Recent studies indicate that these neurochemical changes are mediated by a polysynaptic
glutamatergic pathway from mPFC that probably innervates the lateral dorsal tegmental
nucleus (LDTg) and pedunculopontine tegmental nucleus (PPTg), which in turn projects
glutamatergic fibers to VTA mesoaccumbens DA neurons (Taber et al., 1995; Carr and
Sesack, 2000; Omelchenko and Sesack, 2005). In addition, mPFC pyramidal neurons
selectively innervate VTA mesocortical DA neurons (Carr and Sesack, 2000), which in
turn affect pyramidal neuron activity (Harte and O'Connor, 2004). Thus, the activation of
both polysynaptic and monosynaptic glutamatergic pathways, which originate in mPFC,
appears to regulate VTA glutamate levels. The polysynaptic pathway that includes the
PPTg appears to be involved in nicotine SA (Corrigall et al., 2001).
To evaluate the significance of enhanced mPFC and VTA ionotropic glutamate
receptor subunit expression during and after chronic nicotine SA (Wang et al., 2007), we
first determined the effects of mPFC NMDA on glutamate neurotransmission by using
dual probe microdialysis to measure extracellular glutamate levels in both mPFC and
VTA. The expression of ionotropic glutamate receptor subunits was also determined after
10 days of extinction from chronic nicotine SA. In addition, we investigated the potential
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roles of the up-regulated mPFC and VTA ionotropic glutamate receptors in the
maintenance of nicotine SA by microinjecting the NMDA or AMPA receptor antagonists,
2-amino-5-phosphonopentanoic acid (AP-5) or 1,2,3,4-tetrahydro-6-nitro-2,3-dioxobenzo[f]quinoxaline-7-sulfonamide (NBQX), into these respective regions and measuring
lever press behavior in rats that chronically self-administered nicotine compared to
sucrose pellets.

3.2. Materials and methods
3.2.1. Materials
(–)-Nicotine hydrogen tartrate (doses expressed as free base), AP-5 and NBQX
were purchased from Sigma-Aldrich (St. Louis, MO). Sodium dihydrogen phosphate
monohydrate, EDTA, methanol, and phosphoric acid were obtained from Fisher
Scientific Co. (Fair Lawn, NJ). Cellulose fiber tubing was purchased from Spectrum
(Laguna Hills, CA), and silica tubing (outer diameter, 148 µm; inner diameter, 73 µm;
TSP 075150) was obtained from Polymicron Technologies Inc. (Phoenix, AZ). Operant
chambers, circuit boards, interface modules and SA software for chronic nicotine SA and
sucrose SA were purchased from Coulbourn Instruments (Allentown, PA) and Med
Associates Inc. (Georgia, VT), respectively.
3.2.2. Animals and surgeries
Adult male Lewis rats (250-270 g, Harlan, Madison, WI) were given access ad
libitum to standard rat chow and water. Rats were individually housed on a 12-h reversed
light cycle (off at 10 A.M., on at 10 P.M.). After 7 d of housing under these conditions,
rats were anesthetized with xylazine-ketamine (13 and 87 mg/kg b.wt., i.m.; SigmaAldrich), and chronic guide cannulae (20-gauge) were stereotaxically implanted into the
ipsilateral mPFC and VTA for the in vivo microdialysis experiment according to the
coordinates of Paxinos and Watson (Paxinos and Watson, 1986). For microinjection
experiments, chronic microinjection cannulae (26-gauge) were stereotaxically implanted
into the bilateral mPFC or VTA according to the coordinates of Paxinos and Watson
(Paxinos and Watson, 1986). Coordinates from bregma with flat skull were: mPFC, AP
+3.0 mm, DV -3.0 mm, ML +0.6 mm; VTA, AP –5.95 mm, DV -7.3 mm, ML +0.9 mm.
Three-five d thereafter, the jugular vein was cannulated under xylazine-ketamine;
animals recovered for 3 d before nicotine self-administration began, while animals used
in the sucrose SA experiment recovered for 7 days after stereotaxic surgery before the
onset of sucrose SA training. All procedures were conducted in accordance with NIH
Guidelines concerning the Care and Use of Laboratory Animals and were approved by
the Animal Care and Use Committee of the University of Tennessee Health Science
Center.
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3.2.3. Procedures for chronic nicotine self-administration and extinction followed
by microdialysis
Nicotine self-administration was performed according to our protocols published
previously (Valentine et al., 1997; Wang et al., 2007). Briefly, immediately following
acute surgical recovery, animals were placed into operant chambers where they resided
for the duration of the study. After a 3 d recovery interval, rats were randomly assigned to
treatment groups and jugular lines were filled with either 1 mM nicotine in 200U/ml
heparinized saline or heparin saline alone. The operant chamber contained two levers
positioned 5 cm above the floor; a green cue light 1 cm above each lever signaled the
availability of nicotine. One lever was randomly assigned as the active lever, which
triggered the pump to deliver one 50 µl bolus injection of nicotine over 0.81 sec per 300
g body weight (0.03mg/kg) or saline; pressing the inactive lever had no consequence.
Without prior training, shaping or food deprivation, rats were allowed to acquire and
maintain self-administration behavior throughout consecutive 23 h sessions for 18 d, and
a microdialysis experiment began on d 19. Specifically, the animals were removed from
their operant chamber at 9 A.M. and transferred to the microdialysis apparatus
approximately 3 h before the first baseline sample was collected.
A second microdialysis experiment was conducted after 10 d of extinction from
nicotine SA. In this study, after 18 d of nicotine SA the 10 d extinction phase was
initiated; pressing the active lever had no programmed consequence and the cue lights
were not illuminated. On d 11 of extinction, a microdialysis experiment was performed
on a group of rats that were naïve to microdialysis.
3.2.4. In vivo microdialysis procedure
Concentric microdialysis probes (1.5 mm for VTA, 2.0 mm for mPFC; MW
cutoff 13,000 Da, outer diameter 235 µm) were constructed in our laboratory, as reported
previously (Fu et al., 2000). The recovery efficiencies for glutamate by 1.5 mm and 2.0
mm probes were 4.7 ± 0.5% (n=4) and 7.5 ± 0.6% (n=5), respectively, and for GABA by
1.5 mm and 2.0 mm probes were 6.6 ± 0.6% (n=3) and 8.7 ± 0.4% (n=3), respectively.
Microdialysis was performed as described previously (Fu et al., 2000). Briefly, on d 19 at
9:00 A.M. during their active (dark) phase, rats were moved into the alert-rat
microdialysis chambers (CMA, Chelmsford, MA) located within a dark isolation room,
lit by a red safe-light; microdialysis probes were inserted into both mPFC and VTA guide
cannulae. Following insertion, probes were perfused (2 µl/min) with Kreb’s Ringer
Buffer (KRB; 147 mM NaCl, 4.0 mM KCl, and 3.4 mM CaCl2 in polished water; 0.2 µm
filter sterilized and degassed) for 2 h. Thereafter, 20-min microdialysate samples were
collected into plastic vials; three consecutive samples were collected to measure basal
glutamate and GABA levels prior to drug administration. mPFC was sequentially
perfused with the following solutions, each for 1 h: KRB, 200 µM NMDA, KRB, 500
µM NMDA, KRB, 100 mM KCl.

34

At the end of each experiment, probe positions were verified by histological
examination. Only data obtained from animals with probes in the correct position were
used for analysis.
3.2.5. HPLC-electrochemical analysis
Mobile phase (100 mM sodium dihydrogen phosphate monohydrate in 15%
methanol v/v in polished water, pH 4.4 with phosphoric acid) was perfused through a
reverse-phase column (4.6 x 80 mm, 3 µm; model HR-80; ESA Inc., Chelmsford, USA)
at 1.5 ml/min, using an ESA Model 582 solvent delivery module. O-phthalaldehyde
(OPA)/sulfite stock solution was made by dissolving 22 mg of OPA in 0.5 ml of ethanol,
and then adding 0.5 ml of 1 M sodium sulfite and 9 ml of 0.1 M sodium tetraborate, pH
10.0. The working OPA/sulfite solution was prepared daily by diluting the stock
OPA/sulfite solution with polished water. Glutamate and GABA were automatically
derivatized, samples were maintained at 12°C, and 27 µL was injected on column by an
ESA 542 autosampler. Electrochemical detection was performed at -400 mV (reduction
electrode 1) and +200 mV (reduction electrode 2) with gain set at 200 nA and guard cell
at 350 mV. Similar to a previous report from our laboratory, the limits of detection for
glutamate and GABA were 25 pg/injection and 0.78 pg/injection, respectively (Fu et al.,
2000). Serially diluted standards containing known quantities of glutamate and GABA
were included in each assay (R2 >0.98).
3.2.6. Brain punches and tissue preparation
On d 11 of extinction from chronic nicotine SA, animals were sacrificed to obtain
brain tissues for western immunoblotting of ionotropic glutamate receptors. The brain
punching procedure and tissue preparation were done according to an established
protocol (Wang et al., 2007). Briefly, rats were anesthetized with isoflurane, decapitated,
and brains were removed and stored at –80 °C. Frozen brain sections, 0.7 mm thickness,
were obtained using arrays of 20 double-edge razor blades, designed and assembled in
our laboratory. The mPFC and VTA were punched out according to the atlas of Paxinos
and Watson (Paxinos and Watson, 1986) using a 20 gauge syringe adapter. Dissected
tissues were immediately transferred to tubes embedded in dry ice and stored at –80 °C
until further processing. Dissected tissues were sonicated in 2% sodium dodecyl sulfate
(SDS) solution for 30 sec in an ice-water bath. Sonicated tissues were centrifuged at
800×g, 5 min. Protein concentrations were measured using the bicinchoninic acid assay
(Pierce, Rockford, IL) with bovine serum albumin (BSA) as the standard.
3.2.7. Western immunoblotting
To determine whether the up-regulated expression of ionotropic glutamate
receptors observed during chronic nicotine SA (Wang et al., 2007) persisted after 10 d of
extinction, western immunoblotting was performed following the protocol published
35

previously (Wang et al., 2007). Briefly, prepared tissue samples were run on 10%
polyacrylamide gels and then transferred to PVDF membrane (Bio-Rad, Hercules, CA) at
4°C overnight. Membranes were blocked by 5% non-fat dried milk for 2 h. Based on the
molecular weight differences between NMDA receptor subunits, AMPA receptor
subunits, and β- actin, blots were carefully cut into three separate sections by visualizing
the molecular weight markers: upper blots were used to detect NMDA receptor subunits,
middle blots to detect AMPA receptor subunits, and lower blots to detect β-actin in order
to evaluate protein loading. Blots then were incubated with the following antibodies:
mouse anti-beta actin (1:1000; Sigma, St. Louis, MO), rabbit anti-glutamate receptor
subtype 1 (GluR1; 1:1000; Upstate, Lake Placid, NY), rabbit anti-GluR 2/3 (1:1000;
Upstate, Lake Placid, NY), goat anti-NMDA receptor subtype 1 (NR1; 1:400; Santa
Cruz, CA) or goat anti-NR 2A (1:200; Santa Cruz) or rabbit anti-NR 2B (1:500; Upstate).
Blots were then washed in TBST and incubated in HRP-conjugated secondary antibodies
(1:3000 for beta actin, 1:1500 for all others). All antibodies were diluted in the same
blocking solution and incubated for 2 h at room temperature or overnight at 4°C. Target
proteins were visualized by Supersignal (Pierce, Rockford, IL) followed by imaging
using a Biorad ChemiDoc with quantitation by Quantity One (Bio-Rad, Hercules, CA).
3.2.8. Sucrose self-administration
In two separate experiments, we examined the effects of blocking mPFC NMDA
receptors or VTA AMPA receptors on sucrose self-administration. Beginning 7 d after
stereotaxic implantation of microinjection guide cannulae into mPFC or VTA, rats were
food-deprived to 18g of standard food pellets per d for the duration of the experiment and
the first training session, using sucrose pellet reinforcement, was initiated 2 d, thereafter.
In each training session, rats were placed in an operant chamber for no longer than 60
min or until 100 sucrose pellets were obtained on an FR1 schedule. The operant chamber
consisted of two levers positioned 7 cm above the floor; a yellow cue light 1 cm above
each lever signaled the availability of sucrose pellets (45 mg, Research Diets, New
Brunswick, NJ). One lever, randomly assigned as active, triggered the delivery of a
sucrose pellet; pressing the inactive lever had no programmed consequence. The delivery
of each sucrose pellet was followed by a 10 sec time-out during which the yellow light
above the active bar was not illuminated and sucrose pellets were not available. The
animals acquired the behavior by d 10 ± 0.97. The sucrose-training phase continued for a
total of 18 d, in parallel to the number of days that animals self-administered nicotine in
other experiments. On d 19, two separate experiments were conducted to determine the
effects of the NMDA or AMPA receptor antagonists, AP-5 or NBQX, on sucrose
reinforced operant behavior.
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3.2.9. Intraparenchymal microinjections after chronic nicotine self-administration
or sucrose self-administration
We examined the effects of blocking either mPFC NMDA receptors or VTA
AMPA receptors in separate groups of rats that self-administered either nicotine or
sucrose. Rats were acclimated to the stress of brain microinjection by handling for 3 min
prior to the start of each sucrose SA training or nicotine SA session. After 18 d of sucrose
or nicotine SA, rats received microinjections in the mPFC or VTA on d 19, 21 and 23, 10
min prior to the test session; they self-administered nicotine or sucrose on the intervening
days. On the 3 test days, each rat that self-administered either nicotine or sucrose
received a microinjection (500 nl/120 sec) of KRB or AP-5 (1.5 µg or 5 µg, bilaterally)
into the mPFC in a counterbalanced order. Similarly, separate groups of rats received
microinjections of KRB or NBQX (0.067 µg or 0.25 µg, bilaterally) into the VTA.
To assess the efficacy of administering AP-5 into the mPFC, a third microdialysis
study was performed. Animals were randomly assigned to 2 groups in which either
NMDA alone or AP-5 and NMDA (volumes and rates of delivery as previously defined)
was microinjected into mPFC. Beginning 10 min thereafter, VTA microdialysates were
collected at 20 min intervals for measurements of glutamate.
3.2.10. Locomotion
To determine whether an intra-VTA microinjection of NBQX impaired
movement, we evaluated the effects of intra-VTA NBQX on locomotion. Locomotor
activity was measured by a Digiscan Micro Monitoring system (Omni-tech Electronics,
Columbus, Ohio). This system consists of an activity box (45×24×19 cm) placed on a
sensor-equipped aluminum frame within a sound-attenuating chamber. The frames
contain 16 light beams and detectors, linked to a computer via a micro analyzer
(Accuscan Instruments Inc., Columbus, Ohio). Movement is detected by a photocell
when the animal interrupts an individual light beam. One day before an actual
experiment, each animal was adapted to the behavioral chamber and injection procedure
for 120 minutes. On experimental days 1, 3 and 5, when locomotor activity data were
collected, each animal was placed in a test chamber 1 h before receiving a microinjection.
Following injections, locomotor activity was recorded in 15 min bins for 2 h.
3.2.11. Data analysis
To determine the specificity of nicotine SA, the number of daily active and
inactive lever presses were compared within each treatment group (i.e., nicotine and
saline) and between groups by two-way analysis of variance (ANOVA; SPSS 13.0, SPSS
Inc., Chicago, IL). Data are expressed as mean ± SEM.
For microdialysis experiments, the peak heights of each analyte were analyzed by
PowerChrom (ADInstruments, Castle Hill, Australia) and concentrations were
37

determined by interpolation of sample peak heights relative to standard curves. In each
animal, the basal glutamate or GABA value was defined as the average of the three
samples collected immediately prior to the administration of NMDA. Group data (mean ±
SEM) were expressed as a multiple of the basal glutamate or GABA level that was
determined for each animal. All statistical analyses of glutamate and GABA levels were
performed by two-way ANOVA with repeated measures (SPSS 13.0; SPSS Inc.,
Chicago, IL) with the exception of analysis of peak incremental responses, which used
one-way ANOVA.
For western immunoblotting, each sample from a rat was run once on each of two
gels. Optical density values for each lane were normalized to β-actin in order to control
for variation in loading and transfer. For each sample, normalized values that had been
averaged between the two blots were used to conduct statistical comparisons (unpaired
student t-test) to identify treatment effects within a region for each subunit. The mean
values of nicotine treatment groups were expressed as a percentage of saline ± SEM.
Treatment differences were considered significant at p<0.05.
Lastly, the effects of AP-5 or NBQX on chronic nicotine or sucrose SA were
examined by one-way ANOVA, followed by Fisher's LSD post hoc tests to detect
differences between vehicle and drug effects. The effects of NBQX on locomotion were
analyzed by two-way ANOVA with repeated measures.

3.3. Results
3.3.1. Chronic Nicotine SA and extinction from nicotine SA
Figure 3.1A shows the acquisition and maintenance of chronic nicotine SA by rats
that were microdialyzed on d19. From d 4 onward, active lever presses (FR1) in the
nicotine SA group were approximately 3-4-fold higher than inactive presses (two-way
ANOVA with repeated measures: F1,10=38.89, p<0.001). In addition, the number of
active lever presses was greater in the nicotine SA than saline group (F1,10=7.21, p<0.05).
There was no difference in active vs inactive lever presses in the saline group (F1,10=0.31,
p>0.05).
The SA profiles of rats that were microdialyzed after extinction from chronic
nicotine SA are shown in Figure 3.1B. Similar to panel A, during the first 18 d, active
lever presses were greater than inactive in the nicotine SA group (F1,6=13.78, p<0.05),
whereas no difference was observed in the saline group (F1,6=0.22, p>0.05). During the
10 d extinction period, active lever presses were no greater in the nicotine group
compared to saline (F1,6=3.71, p>0.05). Furthermore, comparing the final 3 d of the
extinction phase to that during nicotine SA, the mean number of active lever presses were
less (extinction vs nicotine SA: 23.9 ± ± 5.2 vs 53.8 ± 6.8 active lever presses;
F1,6=12.11, p<0.05).
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Figure 3.1. Lever press activity during chronic nicotine self-administration (SA) and
extinction. (Panel A) Adult male Lewis rats acquired nicotine SA (0.03mg/kg
b.wt./injection, iv) without prior training, priming or food deprivation when the drug was
available 23 h/d from d 1-18. Two way ANOVA with repeated measures revealed that
active lever presses were greater than inactive presses in the nicotine (Nic) group
(F1,10=38.89, p<0.001; n=7), but not in the saline (Sal) group (F1,10=0.31, p>0.05; n=5).
Comparing treatment groups, active lever presses were greater in the Nic than Sal group
(F1,10=6.79, p<0.05). (Panel B) A separate cohort of rats self-administered Nic or Sal for
18 d, followed by 10 d of extinction. Two way ANOVA with repeated measures showed
that, after extinction, active lever presses in the Nic group (n=4) were no longer different
from the Sal (n=4) group (F1,6=3.71, p>0.05). In addition, the mean number of active
lever presses during the last 3 d of the late maintenance phase (d 16-18) were greater than
during the final 3 d of the extinction period (e.g., d 26-28) (F1,6=12.11, p>0.05). Data are
expressed as mean ± SEM.
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3.2. mPFC and VTA glutamate responsiveness to intra-mPFC NMDA during
chronic nicotine SA
Histological evaluation was performed to determine whether the membrane
region of microdialysis probes and the tip of microinjection cannulae were within mPFC
and VTA. Figure 3.2 shows the neuroanatomical location of these probes and cannulae
from rats that were included in the data analyses.
On d 19 of nicotine and saline SA, two sequential doses of NMDA were
administered via the mPFC microdialysis probe during dual probe (mPFC and VTA)
microdialysis of freely moving rats. Chronic nicotine SA did not affect basal glutamate
levels in the mPFC (108.4 ± 16.1 vs 93.1 ± 17.9 pg/µl for nicotine and saline SA,
respectively; p>0.05) or VTA (21.7 ± 4.1 vs 20.9 ± 3.7 pg/µl for nicotine and saline SA,
respectively; p>0.05). Figure 3.3A shows that nicotine SA enhanced the mPFC glutamate
release induced by 200 µM NMDA (two-way ANOVA: F1,10=6.76, p<0.05), but not by
500 µM NMDA (F1,10=0.91, p>0.05). Further analysis of the same data, expressed as
peak incremental glutamate responses (Figure 3.3B), showed that both nicotine SA and
the dose of NMDA affected glutamate release (two-way ANOVA: F1,10=15.77, p<0.01
and F1,10=31.13, p<0.001, respectively). Additionally, nicotine SA amplified the effects
of both 200 µM and 500 µM NMDA (one-way ANOVAs: F1,10=9.71, p<0.05 and
F1,10=8.74, p<0.05, respectively). In contrast, the mPFC glutamate response to 100 mM
KCl was not affected by nicotine SA (F1,10=0.99, p>0.05).
Figure 3.3C, shows the time course of glutamate release in the VTA in response
to different concentrations of intra-mPFC NMDA or 100 mM KCl on d 19 of chronic
nicotine SA. Nicotine SA amplified the release of VTA glutamate stimulated by 200 µM
and 500 µM NMDA (two-way ANOVAs: F1,10=6.36, p<0.05 and F1,10=5.96, p<0.05,
respectively). The peak incremental VTA glutamate responses (Figure 3.3D) were
affected by nicotine SA and the dose of NMDA (F1,9=32.21, p<0.001 and F1,9=18.73,
p<0.01, respectively), but there was no interaction between these variables (F1,9=2.33,
p>0.05). Additionally, the peak glutamate responses to 200 µM and 500 µM NMDA
were both increased by nicotine SA (one-way ANOVAs: 200 µM NMDA: F1,9=16.99,
p<0.01; 500 µM NMDA: F1,8=16.67, p<0.01). Lastly, nicotine SA did not affect the peak
incremental glutamate response to 100 mM KCl (F1,9=0.17, p>0.05). Therefore, chronic
nicotine SA augmented glutamate responsiveness to NMDA in mPFC and VTA without
affecting basal levels of glutamate in these regions.
3.3.3. mPFC and VTA glutamate responsiveness to intra-mPFC NMDA after
extinction from chronic nicotine SA
On d 11 following the cessation of nicotine SA, animals were microdialyzed to
assess the persistence of glutamate hyper-responsiveness to intra-mPFC NMDA. In both
mPFC andVTA, basal glutamate levels were unaffected by prior nicotine SA (nicotine vs
saline SA: 102.0 ± 18.8 vs. 93.8 ± 15.9 pg/µl in mPFC and 27.8 ± 6.0 vs. 34.0 ± 10.0
pg/µl in VTA; p>0.05 for both comparisons).
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Figure 3.2. Schematic representation of the positions of all microdialysis probes and
microinjection cannulae in the rat mPFC and VTA. Coronal brain sections were
analyzed to verify the position of the membrane segment of each microdialysis probe and
microinjection cannulae (the membrane regions of probes are indicated by line segments
and the tips of microinjection cannulae by dots). All animals used in these investigations
are represented. mPFC and VTA diagrams are 3.0 mm anterior and 5.95 mm posterior to
bregma, respectively (adapted from Paxinos and Watson, 1986).
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Figure 3.3. Chronic nicotine SA enhanced glutamate release in the mPFC and VTA
induced by intra-mPFC NMDA (administered by reverse microdialysis). Glutamate
was measured in microdialysates obtained concurrently from both brain regions. Basal
levels of glutamate in mPFC and VTA were unaffected by nicotine SA. (Panel A) In
mPFC, glutamate responses to NMDA (200 µM and 500 µM) and 100 mM KCl were
determined on d 19 of SA. Two-way ANOVA with repeated measures revealed that
nicotine SA (Nic; n=7) amplified the glutamate response to 200 µM NMDA in
comparison to saline SA (Sal; n=5) (F1,10=6.76, p<0.05). (Panel B) In mPFC, the
glutamate peak incremental responses were calculated from the data in panel A. One-way
ANOVAs indicated that nicotine SA increased the peak incremental response induced by
each dose of NMDA (200 µM NMDA, F1,10=9.71, p<0.05; 500 µM NMDA, F1,10=8.74,
p<0.05). (Panel C) In VTA, the glutamate responses to NMDA and KCl were determined
on d 19 of SA. Nicotine SA (n=7) amplified the glutamate responses to 200 µM and 500
µM NMDA (n=5) (two-way ANOVAs: F1,10=6.36, p<0.05 for 200 µM NMDA;
F1,10=5.96, p<0.05 for500 µM NMDA). (Panel D) In VTA, the glutamate peak
incremental responses were calculated from the data in panel C. NMDA dosedependently stimulated glutamate release (two-way ANOVAs: F1,9=18.73, p<0.01). The
glutamate responses to both doses of NMDA were enhanced by nicotine SA (one-way
ANOVAs: 200 µM NMDA, F1,9=16.99, p<0.01; 500 µM NMDA F1,9=16.67, p<0.01).
Data are expressed as mean ± SEM. *, p<0.05; **, p<0.01 comparing Nic vs. Sal SA at
the same dose of NMDA.
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On d 11 following the extinction of nicotine SA, Figure 3.4A shows that NMDAinduced glutamate release in mPFC was no longer enhanced by the prior selfadministration of nicotine. (F1,6=0.50, p>0.05). Additionally, the glutamate response was
greater to 500 µM than 200 µM NMDA (F1,6=16.91, p<0.01). Similarly, in the VTA,
Figure 3.4B shows the persistence of dose-dependent NMDA-induced glutamate release
(F1,6=18.86, p<0.01) and the absence of enhancement by prior nicotine SA (F1,6=0.02,
p>0.05). Hence, glutamate hyper-responsiveness was no longer detected in mPFC or
VTA by d 11 after cessation of chronic nicotine SA.
3.3.4. mPFC and VTA GABA responsiveness to intra-mPFC NMDA during
chronic nicotine SA
GABA levels were measured to evaluate whether nicotine SA altered GABA
levels in association with the foregoing changes in glutamate release. Chronic nicotine
SA did not affect basal GABA levels in the mPFC or VTA (nicotine vs saline SA:
1.1 ± 0.3 vs 1.5 ± 0.3 pg/µl in mPFC, p>0.05; 1.2 ± 0.3 vs 1.7 ± 0.2 pg/µl in VTA,
p>0.05). Figure 3.5A shows that mPFC GABA levels were stimulated by 200 and 500
µM NMDA (200 µM NMDA: F1,14=17.41, p<0.01; 500 µM NMDA: F1,14=6.18, p<0.05),
but were not affected by nicotine SA (F1,6=0.45, p>0.05) (data were combined from both
treatment groups for analysis of NMDA effects in Figs. 3.5A,B). In contrast, VTA
GABA (Figure 3.5B) was not increased by intra-mPFC NMDA (200 µM NMDA:
F1,10=2.18, p>0.05; 500 µM NMDA: F1,10=3.09, p>0.05). Intra-mPFC KCl stimulated
GABA release in both regions (F1,14=32.87, p<0.001 for mPFC; F1,10=19.56, p<0.01 for
VTA); the data showing a 20-fold increase is not illustrated in Figure 3.5A. In summary,
nicotine SA had no effect on basal or NMDA induced GABA release in the mPFC or
VTA.
3.3.5. Expression of ionotropic glutamate receptor subunits in the mPFC and VTA
after extinction from nicotine SA
We have previously reported that specific ionotropic glutamate receptor subunits,
in mPFC and VTA, are up-regulated by chronic nicotine SA (Wang et al., 2007). To
further evaluate the association between glutamate hyper-responsiveness and receptor
subunit expression, these specific subunits were quantified by western immunoblotting of
mPFC and VTA extracts obtained from animals after 10 d of extinction from nicotine
SA. Representative gels from each treatment group are shown in Figure 3.6. NMDA
receptor NR2A and NR2B subunits were both visualized as single bands at
approximately 180 kDa. In contrast to the up-regulation of these subunits in mPFC during
nicotine SA (Wang et al., 2007), after 10 d of extinction this was not longer evident
(Figure 3.6A). The GluR1 and GluR2/3 subunits in VTA were each single bands
visualized at 106 kDa and 110 kDa, respectively (Figure 3.6B). The up-regulated
expression of GluR2/3, previously reported during nicotine SA(Wang et al., 2007), did
not persist after 10 d of extinction. Therefore, after extinction from chronic nicotine
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Figure 3.4. After extinction from chronic nicotine SA, glutamate release in the
mPFC (panel A) and VTA (panel B), induced by intra-mPFC NMDA, was not
enhanced by prior nicotine SA. Glutamate was measured in concurrent microdialysates
obtained from both brain regions. Basal levels of glutamate in mPFC and VTA were
unaffected by prior nicotine SA. After 10 d of extinction, two way ANOVA with
repeated measures indicated that both the mPFC and VTA glutamate responses induced
by intra-mPFC NMDA (200 or 500 µM; administered by reverse microdialysis) or KCl
were not affected by prior nicotine SA [mPFC (panel A):F1,6=0.50, p>0.05; VTA (panel
B): F1,6=0.02, p>0.05; n=4 for Nic and Sal].
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Figure 3.5. GABA responses in the mPFC (panel A) and VTA (panel B), induced by
intra-mPFC NMDA, were not enhanced by prior nicotine SA. GABA levels were
measured on the microdialysates obtained in the experiments shown in Figure 3. Two
way ANOVA with repeated measures showed that the mPFC and VTA GABA responses
to 200 or 500 µM NMDA were not affected by nicotine SA [mPFC (panel A): F1,6=0.45,
p>0.05; VTA (panel B): F1,4=0.51, p>0.05; n=3-5).
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Figure 3.6. After extinction of nicotine SA, the mPFC and VTA levels of the
ionotropic glutamate receptor subunits, NR1, NR2A, NR2B, GluR1 and GluR2/3
were unaffected by prior nicotine SA. Following regional brain microdissection and
punching, tissue extracts were prepared in SDS, separated by electrophoresis, and then
subjected to western immunoblotting and quantitation, as described in the Methods. For
all subunits, data were normalized to β-actin levels and then converted to mean
percentage of saline (± SEM) for each subunit. Representative blots comparing saline (S)
vs. nicotine (N)-treated animals are shown for each subunit. (Panel A) In mPFC, the
previously reported enhancement of NMDA receptor subunit expression (e.g., NR2A and
NR2B) by nicotine SA was no longer detectable (unpaired student t-test, p>0.05 for each
subunit; n=4 per group) (Wang, Chen et al., 2007). (Panel B) Similarly, in the VTA, the
reported elevation of the AMPA receptor subunit, GluR2/3, during nicotine SA, was not
detected after extinction (unpaired student t-test, p>0.05 for each subunit; n=4 per group).
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SA, there was no longer evidence of enhanced glutamate receptor subunit expression in
mPFC or VTA, nor glutamate hyper-responsiveness to the intra-mPFC administration of
NMDA.
3.3.6. The effects of blockade of mPFC NMDA receptors on the maintenance of
chronic nicotine SA and sucrose SA
To evaluate the potential role of mPFC NMDA receptors in the maintenance of
chronic nicotine SA in comparison to sucrose SA, in two separate groups of animals, the
NMDA receptor antagonist, AP-5 (1.5 or 5 µg/side), was microinjected into mPFC
bilaterally 10 min before the initiation of an SA session. On d 19, 21 and 23, during both
nicotine SA and sucrose SA, AP-5 or KRB was administered in a counterbalanced order.
The intra-mPFC microinjection of AP-5 had no effect on active lever presses or the time
required to obtain 100 sucrose pellets during chronic nicotine SA (p>0.05; Figure 3.7A)
and sucrose SA (p>0.05; Figure 3.7B), respectively. In a separate experiment, the
pharmacological efficacy of the foregoing microinjection of AP-5 was validated by
microdialyzing the VTA following bilateral intra-mPFC NMDA ± AP-5 microinjection.
AP-5 (5 µg/side) abolished the release of glutamate in the VTA (F1,3=31.84, p<0.05; data
not shown). Therefore, NMDA receptors located in the mPFC are not required to
maintain chronic nicotine or sucrose SA.
3.3.7. The effects of blockade of VTA AMPA receptors on the maintenance of
chronic nicotine SA and sucrose SA
We have reported that glutamate receptor subunits (e.g., GluR2/3) up-regulate in
the VTA during chronic nicotine SA (Wang et al., 2007). Therefore, experiments were
designed to evaluate whether the AMPA receptor antagonist, NBQX, reduced chronic
nicotine SA in comparison to sucrose SA, in two separate groups of animals; NBQX
(0.067 or 0.25 µg/side) or KRB was microinjected into VTA prior to SA sessions on d
19, 21 and 23 in each paradigm. NBQX (0.25µg/side) reduced the number of active lever
presses during nicotine SA (Figure 3.8A) and increased the time required to obtain 100
sucrose pellets during sucrose SA (Figure 3.8B) (F2,27=8.89, p<0.01 for chronic nicotine
SA; F2,15=35.59, p<0.001 for sucrose SA). To determine whether the reduction in operant
responding reflected an impairment of locomotion, we tested the effect of the intra-VTA
administration NBQX (0.25 µg/side) on locomotion (Figure 3.8C). Pre-treatment with
NBQX had no effect on locomotion (F2,15=0.04, p>0.05). Therefore, AMPA receptors in
the VTA are required for nicotine reinforced and sucrose reinforced operant behaviors.
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Figure 3.7. The NMDA receptor antagonist, AP-5, did not affect the maintenance of
chronic nicotine or sucrose SA. Using a counterbalanced design in two separate cohorts
of animals (nicotine SA, panel A; sucrose SA, panel B), each animal received AP-5 (1.5
and 5 µg/side) and KRB microinjected into mPFC 10 min before the initiation of daily
test sessions on d 19, d21, and d 23, after 18 d of nicotine or sucrose SA. Animals selfadministered nicotine or sucrose on d 20 and 22 without receiving mPFC injections.
(Panel A) Active lever presses, expressed as the ratio of presses on the treatment
day/presses on the preceding day without treatment, were not altered by AP-5 in the
nicotine SA group (one way ANOVA: F2,15=0.25, p>0.05, n=6). (Panel B) The time
required to obtain 100 sucrose pellets in response to lever pressing (FR1) was expressed
as the ratio of time required on the treatment day/time required on the preceding day
without treatment. This ratio was not affected by intra-mPFC AP-5 (one way ANOVA,
F2,25=0.44, p>0.05, n=8-10 per group).
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Figure 3.8. The AMPA receptor antagonist, NBQX, reduced active lever pressing
during the maintenance phase of chronic nicotine and sucrose SA when
administered into the VTA. Using a counterbalanced design in two separate cohorts of
animals (nicotine SA, panel A; sucrose SA, panel B), each animal received NBQX (0.067
and 0.25 µg/side) and KRB microinjected into VTA 10 min before the initiation of daily
test sessions on d 19, d21, and d 23, after 18 d of nicotine or sucrose SA. Animals selfadministered nicotine or sucrose on d 20 and 22 without receiving VTA injections. (Panel
A) Active lever presses, expressed as the ratio of presses on the treatment day/presses on
the preceding day without treatment, were reduced by intra-VTA NBQX at 0.25 µg/side
(one way ANOVA, F2,27=8.90, p<0.01, n=10). (Panel B) The time required to obtain 100
sucrose pellets in response to lever pressing (FR1) was expressed as the ratio of time
required on the treatment day/time required on the preceding day without treatment. This
ratio was increased by intra-VTA NBQX at 0.25 µg/side (one way ANOVA, F2,15=35.60,
p<0.001, n=6). (Panel C) Intra-VTA NBQX did not affect locomotion (two way ANOVA
with repeated measures, F2,15=0.04, p>0.05). *, p<0.01, **, p<0.001, compared to intramPFC or -VTA microinjection of KRB; #, p<0.01, ##, p<0.001, compared to intra-mPFC
or -VTA microinjection of NBQX 0.067 µg/side.
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3.4. Discussion
Though many of the neurochemical and molecular effects of nicotine have been
well studied, the drug’s long-term neuroadaptive effects, specifically within the
mesocortical glutamatergic pathway, are largely undefined. Based on recent evidence
showing that NMDA and AMPA receptors are up-regulated in the mPFC and VTA,
respectively, during chronic nicotine SA (Wang et al., 2007), we hypothesized that there
may exist a hyperglutamatergic state of neurotransmission between the mPFC and VTA
during chronic nicotine SA. The current study revealed enhanced glutamate
responsiveness to stimulation with NMDA, not only at the site of perfusion within the
mPFC but also from mPFC afferents to the VTA during the late maintenance phase of
chronic nicotine SA (day 18). Enhanced glutamate responsiveness was only demonstrable
during nicotine SA, and was undetectable after extinction. Furthermore, the previously
reported up-regulation of ionotropic glutamate receptors did not persist after extinction.
Behavioral studies indicated that the NMDA receptors in the mPFC were not required to
maintain chronic nicotine SA, while VTA AMPA receptors were required. Blockade of
AMPA receptors in the VTA decreased nicotine reinforced and sucrose reinforced
operant behaviors without affecting the locomotion. Thus, neuroadaptive changes
involving ionotropic glutamate receptors and NMDA receptor-dependent glutamate
neurotransmission between mPFC and VTA are induced by nicotine SA. VTA AMPA
receptors are necessary for the maintenance of nicotine SA.
The glutamatergic regulation of VTA dopamine neurons undergoes adaptive
changes that are involved in the reinforcing effects of nicotine (Fagen et al., 2003).
Nicotine stimulates dopamine secretion in the NAcc, an effect common to all drugs of
abuse, in part by increasing glutamate release in the VTA, which in turn induces burst
firing of dopamine neurons in the VTA (Grenhoff et al., 1986; Svensson et al., 1990;
Mansvelder and McGehee, 2002). Nicotine induces long-term potentiation (LTP) of these
dopamine neurons that depends on pre- and post-synaptic changes (Mansvelder and
McGehee, 2000). The present study showed that 200 µM NMDA, perfused into mPFC by
microdialysis, significantly stimulated glutamate release in the mPFC and VTA of
nicotine self-administering rats, but not controls. Although a concentration of 500 µM
NMDA induced glutamate release in the mPFC and VTA of both treatment groups,
glutamate levels were significantly greater in the nicotine SA group. Thus, depending on
the dose of NMDA, concurrent nicotine SA either potentiated or amplified glutamate
release. In the VTA, these were not local effects of NMDA, indicating that nicotine SA
had effected a state of enhanced glutamate neurotransmission.
Enhanced glutamate neurotransmission has been observed after extinction of
cocaine and amphetamine. Ten d after 5 daily cocaine treatments, an injection of cocaine
stimulated significantly more NAcc glutamate release in animals pretreated with the drug
compared to saline (Reid and Berger, 1996). Similarly, intra-VTA AMPA stimulated
more glutamate release in the VTA and NAcc of rats withdrawn from repeated daily
injections of amphetamine than saline (Giorgetti et al., 2001). Thus, relatively few
exposures to a psychostimulant are sufficient to induce a lasting state of enhanced
glutamate responsiveness to the drug or to AMPA. Apparently, the amplification of
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glutamate responses to intra-VTA AMPA is indirect, mediated by the enduring effects of
amphetamine on AMPA-stimulated dopamine and/or GABA neurotransmission in NAcc
and VTA (Giorgetti et al., 2001).
The mechanism(s) whereby nicotine SA potentiates or amplifies NMDAstimulated glutamate secretion in mPFC and VTA are unknown, although the increased
expression of NR2A and NR2B subunits and possibly NMDA receptors, expressed on
pyramidal neurons in mPFC (Huntley et al., 1994), is likely to be involved. If the increase
in mPFC NMDA receptor expression occurs on pyramidal neurons and is proportional to
that reported previously for the subunits (Wang et al., 2007), the sensitivity to intramPFC NMDA would increase significantly; this would be likely to account for the
amplification and possibly the potentiation of glutamate release during nicotine SA.
Notwithstanding this, the potential role of GABA is worthy of consideration. GABA
interneurons in mPFC inhibit pyramidal neurons (Tzschentke and Schmidt, 2000), and
several reports have shown that GABA neurotransmission is affected by nicotine.
Chronic injections of nicotine abolished the inhibitory effect of GABAB receptors on
electrically evoked dopamine release in the VTA (Amantea and Bowery, 2004). In the
PFC, GABAB receptor mRNA was reduced by chronic exposure to nicotine, suggesting
that nicotine SA might diminish the inhibitory regulation of pyramidal neurons (Li et al.,
2004). If this occurs, one might expect this defect to spare GABA interneurons, since
basal and NMDA-stimulated GABA release in mPFC was unaffected by nicotine SA in
the present study. In contrast, a reduction in the expression of GABAB receptors on PFC
GABA interneurons would probably be accompanied by increased basal GABA levels
and enhanced NMDA-induced GABA release. Inhibitory regulation of mPFC pyramidal
neurons has been demonstrated in experiments showing that stimulation of VTA
glutamate release by intra-mPFC KCl was enhanced by blockade of mPFC GABAB
receptors (Harte and O'Connor, 2005). Thus, it is conceivable that both enhanced
expression of NMDA receptors and reduced expression (or function) of GABAB
receptors on mPFC pyramidal neurons are responsible for the enhanced release of
glutamate by NMDA.
After extinction from chronic nicotine SA, we no longer detected the
augmentation of NMDA-induced glutamate release in mPFC or VTA. Furthermore, the
increased expression of ionotropic glutamate receptor subunits in these regions had
reverted to control levels. The reversal of adaptive changes in neurotransmission and
receptor expression is consistent with findings from several psychostimulant studies
showing that cellular and neurochemical adaptations are often transient. For example,
decreased levels of VTA Giα and Goα proteins, detectable at 1 h or 6 h after repeated
injections of cocaine, were not present by 24 h (Nestler et al., 1990; Striplin and Kalivas,
1992). In a neurochemical study, AMPA-stimulated glutamate release in the VTA and
NAcc was only augmented at 3 d, but not 14 d, after a regimen of repeated amphetamine
treatments (Giorgetti et al., 2001). Finally, an electrophysiological study showed that the
AMPA-induced firing of VTA dopamine neurons in vitro was enhanced at 3 but not 14 d
following repeated exposure to cocaine or amphetamine (Zhang et al., 1997). The latter
two studies indicate that the enhanced VTA glutamate neurotransmission following
exposure to psychostimulants is transient and involves AMPA receptors, which were up51

regulated in our previous study (Wang et al., 2007). Taken together, these studies all
demonstrate that repeated exposure to psychostimulant drugs commonly induce
molecular and neurochemical adaptations involving glutamate and dopamine
neurotransmission in the mesolimbic system.
Since we found that glutamate receptor expression and glutamate
neurotransmission were enhanced on d 19 of nicotine SA, studies were designed to
determine whether NMDA and AMPA receptor antagonists impaired nicotine SA at this
time. AP-5, an NMDA receptor antagonist, was microinjected bilaterally into the mPFC,
where NMDA receptor subunit expression was increased (Wang et al., 2007); neither
nicotine SA nor sucrose-reinforced operant behavior was affected. These observations are
consistent with reports showing that blockade of NMDA receptors within the mPFC
impaired the acquisition but not the expression of appetitive instrumental learning
(Baldwin et al., 2000; Baldwin et al., 2002). Subsequently, NBQX, an AMPA receptor
antagonist, was microinjected into the VTA, where GluR2/3 receptor subunit expression
was increased (Wang et al., 2007); at the higher dose of NBQX, both nicotine SA and
sucrose reinforced operant behavior was significantly inhibited. These observations
suggest that VTA AMPA receptors are required for the maintenance of both operant
behaviors. Thus, drug-induced neuroplasticity, involving the up-regulation of VTA
GluR2/3-containing AMPA receptors, may not underlie the efficacy of NBQX. Thus, we
hypothesize that VTA AMPA receptors may generally be required to maintain these
appetitive operant behaviors.
AMPA receptors in the VTA are involved in behavioral, neurochemical and
electrophysiological changes induced by chronic exposure to abused drugs. These
receptors in the VTA are required for the initiation of behavioral sensitization to cocaine
(Licata et al., 2004), and although the blockade of AMPA receptors by systemically
administered antagonists failed to inhibit the expression of behavioral sensitization to
these psychostimulants (Li et al., 1997), such blockade was effective against ethanol
sensitization (Broadbent et al., 2003). VTA AMPA receptors are also necessary for the
initiation of morphine conditioned place preference (CPP) (Harris et al., 2004).
Neurochemically, repeated exposure to amphetamine has been shown to augment the
release of mesolimbic dopamine and glutamate by intra-VTA AMPA (Giorgetti et al.,
2001). Electrophysiologically, AMPA receptors have been shown to stimulate and
enhance burst firing of VTA dopamine neurons (Meltzer et al., 1997). Burst firing of
dopamine neurons has been shown to be more efficient than single spike firing in the
enhancement of phasic dopamine release and the transduction of salient stimuli (Chergui
et al., 1993; Overton and Clark, 1997; Schultz et al., 1997). Nicotine increased the burst
firing of VTA DA neurons (Grenhoff et al., 1986; Svensson et al., 1990) by stimulating
glutamate release through presynaptic α7 receptors in VTA (Schilstrom et al., 2003).
Additionally, a single injection of nicotine or other drugs of abuse (e.g. cocaine, damphetamine, ethanol) induced an increase in the strength of synapses on VTA dopamine
neurons (i.e. increased AMPAR/NMDAR excitatory postsynaptic currents) (Saal et al.,
2003). This is consistent with our report showing up-regulation of VTA GluR2/3, but not
NMDA receptors, in the VTA during chronic nicotine SA (Wang et al., 2007). Taken
together, these studies indicate that VTA AMPA receptors appear to manifest enhanced
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responsiveness and/or expression induced by various classes of abused drugs. These
changes in function and expression of VTA AMPA receptors have been associated with
enhanced dopamine and glutamate neurotransmission, and may be involved in behavioral
sensitization and conditioned place preference to specific drugs of abuse. The current
study indicates that VTA AMPA receptors are also involved in the maintenance of
nicotine and food reinforced operant behavior.
These studies demonstrate the enhancement of glutamate neurotransmission in
mPFC and VTA due to mPFC stimulation by NMDA during chronic nicotine SA. Based
on recent neuroanatomical studies, the VTA glutamate measured herein may reflect two
sources: direct glutamatergic projections from mPFC to VTA and glutamatergic fibers
from LDTg and PPTg to VTA, activated by mPFC glutamatergic efferents to LDTg and
PPTg (Tzschentke and Schmidt, 2000; Omelchenko and Sesack, 2005; Omelchenko and
Sesack, 2007). This enhancement of glutamate neurotransmission is a transient adaptive
change that correlates with the up-regulation of ionotropic glutamate receptors, requires
coincident nicotine SA, and may specifically depend on the enhanced mPFC expression
of NMDA receptors containing NR2A and NR2B subunits. Blockade of NMDA
receptors in the mPFC did not affect the maintenance of chronic nicotine SA, while
inhibition of VTA AMPA receptors decreased both nicotine and sucrose SA, indicating
that VTA AMPA receptors may generally be required to maintain appetitive operant
behavior.
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Chapter 4. Discussion
4.1. The cellular distribution of up-regulated mPFC NMDA receptors
and VTA AMPA receptors
In the current study, we demonstrated that, after 18 d of nicotine SA, the
expression of mPFC NR2A and NR2B receptor subunits was increased by 67% and 83%,
respectively, and the VTA GluR2/3 subunit was up-regulated by 34% (Wang et al.,
2007). These nicotine-SA-induced increases in mPFC NR2A and 2B subunits are likely
to be incorporated into functional NMDA receptors, since previous studies indicate that
the availability of NR2 subunits, but not the NR1 subunit, may be a limiting variable in
the expression of intact NMDA receptors on the plasma membrane (see Chapter 2
Discussion). However, the functional significance of these up-regulated ionotropic
glutamate receptors is largely unknown. Therefore, we examined the hypothesis that
there may exist a hyperglutamatergic state of neurotransmission between mPFC and
VTA. In rats self-administering nicotine for 18 d, intra-mPFC perfusion of NMDA
induced glutamate release in the mPFC and VTA that was potentiated or amplified
compared to rats self-administering saline. Thus, it is plausible that up-regulation of
ionotropic glutamate receptors within the mPFC and VTA may be one of the underlying
mechanisms that contributes to the enhanced glutamate neurotransmission between these
brain regions, depending upon their expression by specific types of neurons.
It has been reported that NMDA receptor subunits are differentially distributed
in the brain at cellular, laminar (e.g. layer V of prefrontal cortex) and regional levels
(Huntley et al., 1994). The expression pattern of NMDA receptors on a certain type(s) of
neuron (e.g. glutamatergic pyramidal neuron or GABAergic interneuron) influences its
functional effects on that neuron and on the microcircuitry within a particular brain
region; this determines the effects of NMDA receptors on local neurotransmitter release
(Huntley et al., 1994). Therefore, the up-regulated mPFC NMDA receptors, specifically
the NR2A and NR2B subunits, might concentrate on a certain type of mPFC neuron,
resulting in enhanced glutamate release in VTA when NMDA is administered into the
mPFC. If the up-regulation of mPFC NMDA receptor expression occurs on pyramidal
neurons and is proportional to that reported previously for the subunits (Wang et al.,
2007), responsiveness to intra-mPFC NMDA would be expected to increase significantly;
this most likely accounts for the observed amplification and possibly the potentiation of
glutamate release during nicotine SA. In contrast, if the up-regulated NR2A and NR2B
subunits were expressed by NMDA receptors located primarily on GABAergic
interneurons in the mPFC, then basal GABA levels would be expected to increase and
glutamate secretion, induced by intra-mPFC NMDA would decrease during nicotine SA.
However, we did not find an increase in basal or NMDA-stimulated GABA release.
Thus, the up-regulated NR2A and NR2B subunits are most likely expressed by NMDA
receptors located on mPFC pyramidal neurons.
In addition to the up-regulation of NMDA receptors, the GABA system may have
a role in enhancing the mPFC glutamate response to NMDA during nicotine SA. GABA
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interneurons in mPFC inhibit pyramidal neurons (Tzschentke and Schmidt, 2000), and
accumulating evidence has shown that GABA neutrotransmission is affected by nicotine
(Amantea and Bowery, 2004; Li et al., 2004; Harte and O'Connor, 2005). For example,
mPFC GABAB receptors are known to be involved in the inhibitory regulation of mPFC
pyramidal neurons, since intra-mPFC KCl-stimulated glutamate release in the VTA was
enhanced by blockade of mPFC GABAB receptors (Harte and O'Connor, 2005). In
addition, after chronic nicotine administration, reduced sensitivity of GABAB receptors
was found in the VTA (Amantea and Bowery, 2004), which may apply to the mPFC, as
well. This reduced sensitivity of GABAB receptors may be due to reduced expression.
Indeed, it has been shown that mPFC GABAB receptor mRNA was reduced by chronic
exposure to nicotine, indicating that nicotine SA might reduce the inhibitory regulation of
pyramidal neurons, if the level of postsynaptic GABAB receptors decreased (Li et al.,
2004). In our studies of nicotine SA, one would expect that presynaptic GABAB receptors
on GABA interneurons were spared from such changes, since basal and NMDAstimulated GABA release in the mPFC were unaffected by nicotine SA. Indeed, upon
intra-mPFC infusion of a GABAB receptor agonist baclofen, glutamate levels in the
mPFC were increased in the cocaine sensitized animals but not in the saline control
animals, in contrast, GABA releases were reduced to similar extents, indicating the
functions of postsynaptic and/or heterosynaptic GABAB receptors were impaired without
affecting presynaptic GABAB autoreceptors after repeated cocaine exposure (Jayaram
and Steketee, 2004) Thus, it is most likely that the increased expression of NMDA
receptors and, perhaps, the reduced expression (or function) of GABAB receptors on
mPFC pyramidal neurons, is responsible for the enhanced mPFC glutamate release
induced by intra-mPFC NMDA.
In the VTA, AMPA receptors have been found on both GABA and DA neurons
(Paquet et al., 1997). In the current study, we found that VTA GluR2/3 subunits of the
AMPA receptor were up-regulated by 34% and VTA glutamate release was enhanced in
rats self-administering nicotine for 18 d. Anterograde and retrograde track-tracing studies
done by Sesack et al., imply that mPFC glutamatergic neurons affect VTA GABA
neurons through monosynaptic and polysynaptic connections to VTA (Carr and Sesack,
2000; Omelchenko and Sesack, 2005; Omelchenko and Sesack, 2007). Thus, changes in
the activity of mPFC glutamatergic neurons will affect the excitability of VTA GABA
neurons directly or indirectly (Tzschentke and Schmidt, 2000). VTA GABA release
consists of somatodendritic and synaptic GABA from VTA GABA projection neurons
and from GABA interneurons, respectively. Since we found that neither basal nor intramPFC NMDA-stimulated GABA secretion was affected by nicotine SA, it is unlikely
that the up-regulated VTA GluR2/3 receptor subunit resides on the plasma membrane of
GABA interneurons. This would most likely have increased basal and NMDA-stimulated
VTA GABA release during nicotine SA, since GABA interneurons synapse with
glutamatergic efferents from mPFC (Carr and Sesack, 2000). Our experiments do not
address the potential for increased GluR2/3 expression by mesoaccumbens or
mesocortical GABA neurons.
VTA dopamine neurons are affected by various drugs of abuse, including
nicotine. A single injection of various drugs of abuse (e.g. cocaine, d-amphetamine,
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ethanol, nicotine) increased the strength of synapses on VTA dopamine neurons (i.e.
increased AMPAR/NMDAR excitatory postsynaptic currents) (Saal et al., 2003),
indicating that an alteration in the function or expression of synaptic AMPA and/or
NMDA receptors on VTA dopamine neurons might be a common mechanism shared by
several abused drugs. Although the underlying molecular mechanism(s) was not
identified, enhanced AMPA receptor subunit expression upon chronic exposure to drugs
of abuse appears to be a common mechanism (Fitzgerald et al., 1996; Wang et al., 2007).
AMPA receptor GluR2/3 subunits are expressed by a majority of VTA dopamine
neurons. An immunocytochemical study has shown that GluR2/3 subunits were found on
63% of tyrosine hydroxylase positive neurons in the VTA. In comparison, GluR1
subunits were found on only 20% of these neurons (Chen et al., 2001). The up-regulated
expression of GluR2/3 subunits in the VTA during chronic nicotine SA suggests there
might be a larger pool of recycling of GluR2/3 subunits in VTA neurons, since these
subunits are known to recycle constitutively which is important for the maintenance of
basal synaptic activity (Passafaro et al., 2001; Shi, Hayashi et al., 2001). Thus, we
postulate that the AMPAR/NMDAR EPSC ratio would be increased if more GluR2/3
subunits reside on the plasma membrane of VTA DA neurons during chronic nicotine
SA.

4.2. Monosynaptic and polysynaptic glutamatergic connections
between mPFC and VTA
The present study revealed enhanced glutamate neurotransmission between mPFC
and VTA based on our observation of amplified or potentiated glutamate responsiveness
in the VTA to stimulation by intra-mPFC NMDA. Recent evidence indicates that mPFC
pyramidal neurons innervate VTA DA neurons via monosynaptic or polysynaptic
connections (Carr and Sesack, 2000; Omelchenko and Sesack, 2005; Omelchenko and
Sesack, 2007). Neuroanatomical tracing studies have demonstrated that mPFC pyramidal
efferent neurons selectively innervate subpopulations of VTA dopamine and GABA
neurons via monosynaptic connections. mPFC glutamatergic efferent pyramidal neurons
synapse selectively on mesocortical but not mesoaccumbens DA neurons, whereas
mesoaccumbens GABA neurons and not mesocortical GABA neurons are innervated by
mPFC pyramidal neurons (Carr and Sesack, 2000).
The monosynaptic type of innervation between mPFC and VTA could not explain
an in vivo microdialysis study showing that blockade of ionotropic glutamate receptors,
using intra-VTA antagonists, decreased basal NAcc dopamine by 30% and blocked DA
release evoked by mPFC stimulation (Taber et al., 1995). This study suggests that a
polysynaptic glutamatergic pathway exists. Indeed, tract-tracing along with triple labeling
revealed that the aforementioned DA release in the NAcc is most likely mediated by a
polysynaptic glutamatergic pathway from mPFC that innervates the laterodorsal
tegmental nucleus (LDTg) and pedunculopontine tegmental nucleus (PPTg), which in
turn projects glutamatergic fibers to VTA mesoaccumbens DA neurons (Carr and Sesack,
2000; Omelchenko and Sesack, 2005). Furthermore, using vesicular glutamate transporter
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subtype 1 and 2 (VGlut1 and VGlut2), as markers for cortical and subcortical glutamate
sources, respectively, it was demonstrated that VGlut2+ axon terminals were more highly
expressed in VTA than VGlut1+ terminals (Omelchenko and Sesack, 2007). This
suggests that the predominant source of glutamate to the VTA is from subcortical areas
(Omelchenko and Sesack, 2007), possibly from LDTg and PPTg (Omelchenko and
Sesack, 2005).
The polysynaptic connection between mPFC and VTA via LDTg and/or PPTg
might play a major role in intra-mPFC NMDA-stimulated glutamate release in VTA
during chronic nicotine SA. A study combining anterograde and retrograde tract-tracing
of LDTg projections to VTA neurons found that LDTg glutamatergic projections
preferentially excite mesoaccumbens DA neurons (Omelchenko and Sesack, 2005). Thus,
the polysynaptic connection between mPFC and VTA, specifically via LDTg, may be
important for regulating VTA mesoaccumbens DA neuron activity. However, further
experiments are needed to clarify the role of LDTg and/or PPTg in the amplification of
NMDA-induced glutamate neurotransmission between mPFC and VTA during chronic
nicotine SA. For example, a study that blocked ionotropic glutamate receptors in the
LDTg and/or PPTg and stimulated with intra-mPFC NMDA during chronic nicotine SA
would indicate to what extent LDTg and/or PPTg are involved.
In summary, the activation of both polysynaptic and monosynaptic glutamatergic
mPFC efferents appears to regulate VTA glutamate levels. The polysynaptic efferents,
possibly via LDTg and or PPTg, may be more important in regulating VTA
mesoaccumbens DA neuron activity. Such efferents may also be the major sources of the
enhanced VTA glutamate, although further experiments are required to test this
hypothesis.

4.3. The potential functional significance of enhanced glutamate
neurotransmission during chronic nicotine SA
The reinforcing effects of nicotine, the major psychoactive component in cigarette
smoke, depend on dopamine secretion in the mesolimbic system of the brain (Corrigall
and Coen, 1989; Corrigall et al., 1992). Recent reports have shown that nicotine acutely
stimulates VTA glutamate release through presynaptic nAChRs, possibly α7 subunits,
which in turn excites VTA DA neurons (Fu et al., 2000; Mansvelder and McGehee,
2000). It has been shown that dopamine release in the NAcc at least partly depends on
VTA ionotropic glutamate receptors. For example, nicotine-stimulated NAcc DA release
is reduced after intra-VTA infusion of the NMDA receptor antagonists (AP-5 or
CGS19755), suggesting NMDA receptors in the VTA are required (Schilstrom et al.,
1998; Fu et al., 2000). VTA DA neurons receive glutamatergic innervation from mPFC
and subcortical areas. Thus, it is conceivable that nicotine also may increase the activity
of VTA dopamine neurons by activating glutamatergic inputs from these areas, which
might be a mechanism in addition to its direct stimulating effect. Indeed, the glutamatedependent burst firing of VTA DA neurons is well documented (see discussion below).
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Consistent with this, in the present study, we found that NMDA-stimulated glutamate
neurotransmission within mPFC and VTA was enhanced during chronic nicotine SA.
VTA dopamine neurons exhibit a “tonic, irregular activity pattern” (Omelchenko
and Sesack, 2005), consisting of single spikes and bursts of action potentials (Overton
and Clark, 1997), from recordings of naïve animals in vivo and in vitro (Sanghera et al.,
1984; Grace and Onn, 1989). Compared with single spike activity, burst firing activity is
more efficient at transducing salient environmental stimuli (Overton and Clark, 1997;
Schultz et al., 1997; Berridge and Robinson, 1998) and enhancing phasic DA release
(Chergui et al., 1993). The fluctuation of phasic DA levels in the mPFC and NAcc may
signal future expectancy (Schultz et al., 1997; Omelchenko and Sesack, 2005), or
attentional shifting (Redgrave et al., 1999). Nicotine has been shown to increase the firing
rate and burst firing of VTA DA neurons (Nisell et al., 1996; Fisher et al., 1998),
contributing to phasic DA release. However, in studies of VTA slice preparations,
nicotine did not induce burst firing (Calabresi et al., 1989), suggesting that nicotinestimulated glutamate release from cortical and subcortical areas is critical for the effect of
nicotine on VTA DA neuronal burst firing activity in vivo. Indeed, burst firing of VTA
DA neurons is critically dependent on mPFC glutamate inputs (Svensson et al., 1990).
Chemical (Murase et al., 1993) or electrical (Gariano and Groves, 1988; Tong et al.,
1996) stimulation of mPFC increases burst firing of VTA DA neurons.
In line with these observations, in the present study, chronic nicotine SA induced
enhanced glutamate release in the mPFC and VTA in response to intra-mPFC NMDA.
This increase in VTA glutamate release may stimulate more burst firing by VTA DA
neurons due to enhanced NMDA receptor sensitivity. Indeed, the spontaneous burst firing
of VTA DA neurons are largely determined by the level of activation of NMDA receptors
on these neurons (Schilstrom et al., 2003). Activation of the NMDA receptor has been
shown to be important for the induction of burst firing activity in the VTA; nicotine does
not induce burst firing in VTA DA neurons in vitro. In contrast, NMDA is still capable of
doing so (Johnson et al., 1992). However, NMDA receptors can only be activated when
neurons are depolarized to remove the Mg2+ blockade. Thus, the enhanced intra-mPFC
NMDA-stimulated glutamate neurotransmission in the VTA may increase the
responsiveness of NMDA receptors on VTA DA neurons by increasing the probability of
depolarization, which would remove the Mg2+ blockade. If the up-regulated GluR2/3
subunit resides on plasma membrane of VTA DA neurons, the synaptic strength (i.e. the
AMPAR/NMDAR EPSC) also could be enhanced, which may further contribute to burst
firing of VTA DA neurons during chronic nicotine SA.

4.4. Enhanced glutamate neurotransmission implicated in behavioral
paradigms affected by chronic administration of drugs of abuse
Behavioral sensitization refers to an enhanced motor-stimulant response to most
abused drugs including cocaine, amphetamine and nicotine, after repeated or intermittent
exposure (Steketee, 2005). Evidence indicates that blockade of ionotropic glutamate
receptors prevents initiation or expression of behavioral sensitization to different drugs of
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abuse (see Chapter 3 Discussion). In addition, it has been shown that repeated exposure
to psychostimulants (e.g. cocaine or amphetamine) induces enhanced glutamate
responsiveness within the mesocorticolimbic system to drugs or to ionotropic glutamate
receptor agonists that were administered under the same treatment paradigms that
induced behavioral sensitization. For example, enhanced glutamate neurotransmission
has been observed after cessation of cocaine and amphetamine injections. Ten d after 5
daily cocaine treatments, an injection of cocaine stimulated significantly more NAcc
glutamate release in animals pretreated with the drug compared to saline (Reid and
Berger, 1996). Similarly, intra-VTA AMPA stimulated more glutamate release in the
VTA and NAcc of rats withdrawn from repeated daily injections of amphetamine than
saline (Giorgetti et al., 2001). Functionally, this enhanced glutamate neurotransmission
might contribute to increased VTA DA neuron responsiveness to glutamate, as measured
by a current-response curve (White et al., 1995) which specifically involves AMPA
receptors (Zhang et al., 1997). Additionally, enhanced VTA AMPA receptor expression
after repeated exposure of drugs of abuse has been documented extensively (see Chapter
2 Discussion). NAcc surface AMPA receptor expression was increased 21 d after the last
injection in cocaine-sensitized animals, but not in rats that did not develop behavioral
sensitization. This suggests that up-regulation of NAcc AMPA receptor surface
expression might contribute to behavioral sensitization (Boudreau and Wolf, 2005). In
line with these evidences, we found a 34% increase in the GluR2/3 subunit and enhanced
glutamate neurotransmission in the VTA. The precise functional significance of this
finding is unknown, however, we demonstrated that VTA AMPA receptors were required
for the maintenance of both chronic nicotine SA and sucrose SA operant behaviors,
suggesting VTA AMPA receptors may be generally required for the maintenance of these
appetitive operant behaviors.
In drug abuse research, reinstatement models, characterized by the cue-, stress- or
drug priming-induced reinstatement of unreinforced lever pressing behavior that was
previously extinguished, are used to understand relapse to drug seeking behavior in
human addicts (Shaham et al., 2003). Enhanced glutamate neurotransmission within the
pathway from mPFC to NAcc core has been shown to be the key mediator of various
forms of relapse to cocaine seeking, such as cocaine-priming induced (McFarland et al.,
2003) and footshock-induced cocaine seeking behavior (McFarland et al., 2004). In
cocaine priming-induced reinstatement, increased glutamate release in the NAcc core
after a cocaine-priming injection was only found in cocaine SA animals, and not in the
yoked saline or yoked cocaine group. Moreover, the enhanced glutamate release in the
NAcc core was not associated with food-induced food seeking behavior nor lever
responding per se. This indicates a positive and specific association between enhanced
glutamate neurotransmission and cocaine-induced reinstatement of cocaine seeking
behavior (McFarland et al., 2003). In addition, enhanced DA release in NAcc core was
found in all groups (e.g. yoked saline, yoked cocaine, cocaine SA) after the cocainepriming injection, suggesting that enhanced DA release might be a secondary effect of
reinstatement of cocaine seeking behavior, rather than the primary cause (McFarland et
al., 2003). Furthermore, when dorsal PFC was inactivated by microinfusion of the
GABAB agonist, baclofen, and the GABAA agonist, muscimol, the enhanced glutamate
release in the NAcc core and cocaine-induced reinstatement of cocaine seeking behavior
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were abolished concurrently, suggesting that the source of the elevated glutamate
secretion in the NAcc core after cocaine challenge was the dorsal PFC (activity
dependent) (McFarland et al., 2003). Similarly, footshock-induced cocaine seeking
behavior was also associated with increased glutamate release in the NAcc core via
dorsal PFC pwrojections (McFarland et al., 2004). Overall, these observations suggest
that enhanced glutamate neurotransmission between mPFC and NAcc core underlies
cocaine-priming and footshock-induced cocaine reinstatement.
In current study, we hypothesized that mPFC NMDA or VTA AMPA receptors,
which up-regulated during chronic nicotine SA, might be required to maintain operant
responding behavior during late maintenance phase of chronic nicotine SA. Data
suggested that mPFC NMDA receptors might not be required to maintain nicotine or
sucrose SA, which is consistent with the notion that blockade of NMDA receptors within
the mPFC impaired the acquisition but not the expression of appetitive instrumental
learning (Baldwin et al., 2000; Baldwin et al., 2002). In contrast, NBQX, an AMPA
receptor antagonist, was microinjected into the VTA, where GluR2/3 receptor subunit
expression was increased (Wang et al., 2007); at the higher dose of NBQX, both nicotine
SA and sucrose reinforced operant behavior was significantly inhibited. Moreover, this
inhibitory effect of NBQX on operant behavior was not due to an inhibitory effect on
locomotion. These observations suggest that VTA AMPA receptors are required for the
maintenance of both operant behaviors.

4.5. Conclusion
In current study, we demonstrated that, after 18 d chronic nicotine SA, iGluRs upregulated in the mesocortical regions, specifically, in the mPFC and VTA. The glutamate
but not GABA release stimulated by intra-mPFC NMDA in the mPFC and VTA was
potentiated or augmented in rats self-administered nicotine compared with rats selfadministered saline, indicating a hyperglutamatergic neurotransmission between mPFC
and VTA. These neurochemical changes appeared to be transient: after 10 d of extinction,
the enhanced glutamate neurotransmission and up-regulated iGluRs were no longer
demonstrable. In addition, blockade of mPFC NMDA receptors did not affect the
maintenance of chronic nicotine SA and sucrose SA. In contrast, blockade of VTA
AMPA receptors inhibited the maintenance of both SA behaviors, suggesting VTA
AMPA receptors may generally be required to maintain appetitive operant behavior. In
summary, the current study demonstrated a transient neuroadaptive change in the
mesocortical glutamate system during chronic nicotine SA, and such changes might
contribute to the augmented mesocorticolimbic dopamine neurotransmission which is
common to all drugs of abuse.
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